<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12249696</article-id><article-id pub-id-type="pmcid-ver">PMC12249696.1</article-id><article-id pub-id-type="pmcaid">12249696</article-id><article-id pub-id-type="pmcaiid">12249696</article-id><article-id pub-id-type="pmid">40650291</article-id><article-id pub-id-type="doi">10.3390/ijms26136514</article-id><article-id pub-id-type="publisher-id">ijms-26-06514</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Psychopharmacological Therapy Positively Modulates Disease Activity in Inflammatory Bowel Disease: A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5347-7641</contrib-id><name name-style="western"><surname>Di Vincenzo</surname><given-names initials="F">Federica</given-names></name><xref rid="af1-ijms-26-06514" ref-type="aff">1</xref><xref rid="af2-ijms-26-06514" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-6807-5796</contrib-id><name name-style="western"><surname>D&#8217;Onofrio</surname><given-names initials="AM">Antonio Maria</given-names></name><xref rid="af3-ijms-26-06514" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Del Gaudio</surname><given-names initials="A">Angelo</given-names></name><xref rid="af1-ijms-26-06514" ref-type="aff">1</xref><xref rid="af2-ijms-26-06514" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chiera</surname><given-names initials="E">Elena</given-names></name><xref rid="af2-ijms-26-06514" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ferrajoli</surname><given-names initials="GF">Gaspare Filippo</given-names></name><xref rid="af4-ijms-26-06514" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-2725-9978</contrib-id><name name-style="western"><surname>Pesaresi</surname><given-names initials="F">Francesco</given-names></name><xref rid="af3-ijms-26-06514" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6963-7494</contrib-id><name name-style="western"><surname>Simonetti</surname><given-names initials="A">Alessio</given-names></name><xref rid="af5-ijms-26-06514" ref-type="aff">5</xref><xref rid="af6-ijms-26-06514" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3007-8162</contrib-id><name name-style="western"><surname>Mazza</surname><given-names initials="M">Marianna</given-names></name><xref rid="af5-ijms-26-06514" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0281-6324</contrib-id><name name-style="western"><surname>Kotzalidis</surname><given-names initials="GD">Georgios Demetrios</given-names></name><xref rid="af5-ijms-26-06514" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4164-3040</contrib-id><name name-style="western"><surname>Pettorruso</surname><given-names initials="M">Mauro</given-names></name><xref rid="af7-ijms-26-06514" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7292-2341</contrib-id><name name-style="western"><surname>Martinotti</surname><given-names initials="G">Giovanni</given-names></name><xref rid="af7-ijms-26-06514" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lopetuso</surname><given-names initials="LR">Loris Riccardo</given-names></name><xref rid="af1-ijms-26-06514" ref-type="aff">1</xref><xref rid="af8-ijms-26-06514" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6230-1779</contrib-id><name name-style="western"><surname>Gasbarrini</surname><given-names initials="A">Antonio</given-names></name><xref rid="af1-ijms-26-06514" ref-type="aff">1</xref><xref rid="af9-ijms-26-06514" ref-type="aff">9</xref><xref rid="af10-ijms-26-06514" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9767-8752</contrib-id><name name-style="western"><surname>Sani</surname><given-names initials="G">Gabriele</given-names></name><xref rid="af3-ijms-26-06514" ref-type="aff">3</xref><xref rid="af5-ijms-26-06514" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5623-2968</contrib-id><name name-style="western"><surname>Fiorino</surname><given-names initials="G">Gionata</given-names></name><xref rid="af11-ijms-26-06514" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8334-7541</contrib-id><name name-style="western"><surname>Scaldaferri</surname><given-names initials="F">Franco</given-names></name><xref rid="af1-ijms-26-06514" ref-type="aff">1</xref><xref rid="af8-ijms-26-06514" ref-type="aff">8</xref><xref rid="af10-ijms-26-06514" ref-type="aff">10</xref><xref rid="c1-ijms-26-06514" ref-type="corresp">*</xref><xref rid="fn1-ijms-26-06514" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8139-9230</contrib-id><name name-style="western"><surname>Camardese</surname><given-names initials="G">Giovanni</given-names></name><xref rid="af5-ijms-26-06514" ref-type="aff">5</xref><xref rid="af9-ijms-26-06514" ref-type="aff">9</xref><xref rid="fn1-ijms-26-06514" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Stolfi</surname><given-names initials="C">Carmine</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-26-06514"><label>1</label>IBD Unit, Digestive Disease center (CeMAD), Department of Translational Medicine and Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy</aff><aff id="af2-ijms-26-06514"><label>2</label>Universit&#224; Cattolica del Sacro Cuore, 00168 Rome, Italy</aff><aff id="af3-ijms-26-06514"><label>3</label>Department of Neuroscience, Section of Psychiatry, Universit&#224; Cattolica del Sacro Cuore, 00168 Rome, Italy</aff><aff id="af4-ijms-26-06514"><label>4</label>Dipartimento di Salute Mentale, Ospedale di Latina, ASL Latina, 04100 Latina, Italy</aff><aff id="af5-ijms-26-06514"><label>5</label>Department of Neuroscience, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy; <email>alessio.simo@gmail.com</email> (A.S.); <email>marianna.mazza@policlinicogemelli.it</email> (M.M.); <email>g.camardese@unilink.it</email> (G.C.)</aff><aff id="af6-ijms-26-06514"><label>6</label>Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77030, USA</aff><aff id="af7-ijms-26-06514"><label>7</label>Department of Neuroscience, Imaging and Clinical Science, University &#8220;G. D&#8217;Annunzio&#8221; Chieti-Pescara, Via Luigi Polacchi, 11, 66103 Chieti, Italy</aff><aff id="af8-ijms-26-06514"><label>8</label>Department of Life Science, Health, and Health Professions, Link Campus University, 00165 Rome, Italy</aff><aff id="af9-ijms-26-06514"><label>9</label>Internal Medicine, Division of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#224; Cattolica del Sacro Cuore, 00168 Rome, Italy</aff><aff id="af10-ijms-26-06514"><label>10</label>CeMAD Translational Research Laboratories, Digestive Disease Center (CeMAD), Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy</aff><aff id="af11-ijms-26-06514"><label>11</label>IBD Unit, Department of Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, 00152 Rome, Italy</aff><author-notes><corresp id="c1-ijms-26-06514"><label>*</label>Correspondence: <email>franco.scaldaferri@policlinicogemelli.it</email>; Tel.: +39-0630156265</corresp><fn id="fn1-ijms-26-06514"><label>&#8224;</label><p>These authors contributed equally to this work and share last authorship.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><volume>26</volume><issue>13</issue><issue-id pub-id-type="pmc-issue-id">491211</issue-id><elocation-id>6514</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>25</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>11</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-14 17:25:33.493"><day>14</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-26-06514.pdf"/><abstract><p>Depression, anxiety, and perceived stress are common comorbidities in patients with inflammatory bowel disease (IBD) and may negatively influence the disease course. Likewise, severe IBD may contribute to the development or worsening of psychiatric symptoms. Despite the established relevance of the gut&#8211;brain axis and frequent use of psychotropic medications in IBD patients, limited evidence exists regarding the effects of psychiatric treatments on gastrointestinal disease activity. Therefore, the aim of this systematic review is to evaluate the effectiveness of psychiatric therapies on gastrointestinal symptoms and disease activity in patients with IBD. The work was conducted in accordance with PRISMA guidelines. Searches were performed across PubMed, Web of Science, and Scopus up to July 2024. Eligible studies evaluated the effectiveness of psychiatric medications&#8212;including antidepressants, antipsychotics, anxiolytics, sedative-hypnotics, mood stabilizers, anticonvulsants, and others&#8212;on at least one gastrointestinal outcome in patients with IBD. Outcomes included changes in commonly used clinical and endoscopic scores for Crohn&#8217;s disease (CD) and ulcerative colitis (UC), number of bowel movements, stool consistency, presence of blood in stool, severity of abdominal pain, as well as in surrogate markers of disease activity following treatment. Out of 8513 initially identified articles, 22 studies involving 45,572 IBD patients met the inclusion criteria. Antidepressants, particularly bupropion, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), venlafaxine, and duloxetine, were associated with improvements in IBD activity scores, including Crohn&#8217;s Disease Activity Index (CDAI) and Simple Endoscopic Score for Crohn&#8217;s Disease (SES-CD) for CD, Mayo score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for UC. Case reports highlighted potential benefits of pregabalin and lithium carbonate, respectively, showed by the reduction in clinical and endoscopic score of disease activity for pregabalin and improvement of UC symptoms for lithium carbonate, while topiramate showed limited efficacy. Clonidine and naltrexone determined the reductions in clinical and endoscopic score of disease activity, including CDAI and Crohn&#8217;s disease endoscopy index severity score (CDEIS) for CD and Disease Activity Index (DAI) for UC. Despite the limited data and study heterogeneity, antidepressants, naltrexone, and clonidine were associated with improvements in IBD activity. Larger, prospective studies are needed to confirm the therapeutic potential of psychiatric medications in modulating IBD activity and to guide integrated clinical management.</p></abstract><kwd-group><kwd>inflammatory bowel disease</kwd><kwd>psychiatric medications</kwd><kwd>gut&#8211;brain axis</kwd><kwd>antidepressants</kwd><kwd>disease activity</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-26-06514"><title>1. Introduction</title><p>Symptoms of depression and anxiety, as well as perceived distress are common comorbid conditions in patients suffering from inflammatory bowel diseases (IBDs), often leading to health-related decreased quality of life and lower adherence to therapeutic programs [<xref rid="B1-ijms-26-06514" ref-type="bibr">1</xref>,<xref rid="B2-ijms-26-06514" ref-type="bibr">2</xref>,<xref rid="B3-ijms-26-06514" ref-type="bibr">3</xref>]. Recent systematic reviews and meta-analyses suggested an estimated prevalence of anxiety disorders in IBD patients of 20.7%, whereas symptoms of anxiety reached 35.1% of patients [<xref rid="B4-ijms-26-06514" ref-type="bibr">4</xref>]. Depression disorders are slightly less prevalent, with rates of 15.2% of IBD patients [<xref rid="B4-ijms-26-06514" ref-type="bibr">4</xref>], whereas symptoms of depression affect up to 25.2% of patients [<xref rid="B5-ijms-26-06514" ref-type="bibr">5</xref>]. Growing evidence indicate an association between stress and flares in IBD activity, with anxiety and depression being more predominant during flares [<xref rid="B6-ijms-26-06514" ref-type="bibr">6</xref>]. IBD course and mental health seem to have a bidirectional relationship and to be reciprocally influenced by the following: patients with IBD and symptoms of depression or anxiety are at increased risk of poorer outcomes, therapy escalation, hospitalization, emergency department attendance, and increased disability whereas the presence of a more severe IBD at baseline appears to be associated with the development of symptoms of depression and anxiety [<xref rid="B7-ijms-26-06514" ref-type="bibr">7</xref>]. Furthermore, the literature reports cases of psychiatric adverse events following treatment with the biologic drugs currently used for the treatment of IBD (e.g., infliximab), even within a few hours after the drug administration [<xref rid="B8-ijms-26-06514" ref-type="bibr">8</xref>].</p><p>Consequently, managing psychiatric symptoms associated with gastrointestinal medical conditions, including those resulting from therapy, is becoming increasingly relevant for all healthcare professionals involved in the care of IBD patients [<xref rid="B9-ijms-26-06514" ref-type="bibr">9</xref>].</p><p>Despite the relative paucity of supporting evidence regarding the pharmacological intervention for psychiatric symptoms, approximately 30% of IBD patients are treated with antidepressants, especially selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) [<xref rid="B10-ijms-26-06514" ref-type="bibr">10</xref>,<xref rid="B11-ijms-26-06514" ref-type="bibr">11</xref>]. This number was even higher in a large-scale survey conducted in Australia, where 47% of the CD patients reported current use of antidepressants and 25% believed that the treatment ameliorated their IBD [<xref rid="B12-ijms-26-06514" ref-type="bibr">12</xref>]. Similarly, the use of anxiolytics, sedatives, and hypnotics is reported in 26% of IBD patients, a rate significantly higher than that observed in the general population [<xref rid="B10-ijms-26-06514" ref-type="bibr">10</xref>]. Antidepressants have been shown to effectively improve anxiety, depression, and the quality of life in IBD patients. Additionally, they contribute to reducing disease activity and alleviating gastrointestinal symptoms, collectively exerting a positive impact on the disease course of IBD [<xref rid="B13-ijms-26-06514" ref-type="bibr">13</xref>].</p><p>In this systematic review, we comprehensively collected all clinical evidence in the literature on the effectiveness of psychiatric therapies in the management of gastrointestinal symptoms of IBD patients. Our focus extended beyond addressing psychiatric comorbidities to encompass the management of IBD itself. Accordingly, the primary objective of our review was to determine the influence of these treatments on specific disease activity outcomes in IBD patients. Secondarily, we discussed the efficacy of these medications on psychiatric outcomes, while also providing practical recommendations regarding the use of specific drugs that may worsen gastrointestinal symptoms.</p></sec><sec id="sec2-ijms-26-06514"><title>2. Material and Methods</title><p>We conducted this systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [<xref rid="B14-ijms-26-06514" ref-type="bibr">14</xref>] (<xref rid="ijms-26-06514-f001" ref-type="fig">Figure 1</xref>).</p><sec id="sec2dot1-ijms-26-06514"><title>2.1. Eligibility Criteria</title><p>Original peer-reviewed reports, clinical trials, retrospective and prospective cohort studies, meta-analysis, systematic reviews, and case&#8211;control studies in the English language were eligible for inclusion. The Population, Intervention, Comparison and Outcome (PICO) characteristics [<xref rid="B15-ijms-26-06514" ref-type="bibr">15</xref>] were as follows: (1) patients diagnosed with IBD, including Crohn&#8217;s disease, ulcerative colitis, and IBD-unclassified (IBD-U); (2) use of psychiatric medications, including antidepressants, antipsychotics (typical and atypical), anticonvulsants, sedative-hypnotics, anxiolytics, stimulants, anti-craving and addiction medications, mood stabilizers, and others (e.g., Clonidine, Modafinil, Suvorexant, etc.); (3) patients receiving standard IBD treatment without psychiatric medications; and (4) changes in gastroenterological (GI) outcomes, including variations in commonly used clinical and endoscopic scores for CD and UC (e.g., Partial Mayo Score (PMS) [<xref rid="B16-ijms-26-06514" ref-type="bibr">16</xref>], Harvey-Bradshaw index (HBI) [<xref rid="B17-ijms-26-06514" ref-type="bibr">17</xref>], Crohn&#8217;s Disease Activity Index (CDAI) [<xref rid="B18-ijms-26-06514" ref-type="bibr">18</xref>], Inflammatory Bowel Disease Questionnaire (IBDQ) [<xref rid="B19-ijms-26-06514" ref-type="bibr">19</xref>], Lichtiger Colitis Activity Index (LCAI) [<xref rid="B20-ijms-26-06514" ref-type="bibr">20</xref>,<xref rid="B21-ijms-26-06514" ref-type="bibr">21</xref>], Endoscopic Mayo score (EMS) [<xref rid="B16-ijms-26-06514" ref-type="bibr">16</xref>], Ulcerative Colitis Endoscopic Index of Severity (UCEIS) [<xref rid="B22-ijms-26-06514" ref-type="bibr">22</xref>], Simple Endoscopic Score for Crohn&#8217;s Disease (SES-CD) [<xref rid="B23-ijms-26-06514" ref-type="bibr">23</xref>], Disease Activity Index (DAI) [<xref rid="B24-ijms-26-06514" ref-type="bibr">24</xref>], etc.), number of bowel movements, stool consistency, presence of blood in stool, severity of abdominal pain, as well as in surrogate markers of disease activity, such as IBD-related hospitalization, IBD-related surgery, or step-up medication in terms of a redeemed prescription of corticosteroids, immunomodulators or biotechnological therapies.</p><p>Clinical studies that evaluated exclusively the post-treatment variation in the quality of life, the psychological symptoms or in any psychiatric outcome of IBD patients were not included in the study. Studies evaluating patients with irritable bowel syndrome (IBS), or other GI disorders different from IBD were excluded, as well as those including patients with an uncertain diagnosis of an IBD. In the case of mixed cohorts, only data from patients that met our eligibility criteria were taken into account. We did not include animal model studies or non-original reports. Because of the likely scarcity of studies with adequate sample size, also case series with less than 10 patients and case reports were considered, without restrictions on publication year. We did not include data presented only as abstracts at conferences.</p></sec><sec id="sec2dot2-ijms-26-06514"><title>2.2. Information Sources and Search Strategy</title><p>A literature search was performed using the following electronic databases: Web of Science (ISI), PubMed, and SCOPUS. The last search was run on 31 July 2024. The terms &#8220;inflammatory bowel disease&#8221;, &#8220;ulcerative colitis&#8221;, &#8220;Crohn&#8217;s disease&#8221;, &#8220;IBD&#8221;, &#8220;UC&#8221;, &#8220;CD&#8221; were matched with the following drugs: Acamprosate OR Agomelatine OR Alprazolam OR Amisulpride OR Amitriptyline OR Amoxapine OR Amphetamine OR Aripiprazole OR Armodafinil OR Asenapine OR Atomoxetine OR Benztropine OR Blonanserin OR Bremelanotide OR Brexanolone OR Brexpiprazole OR Buprenorphine OR Bupropion OR Buspirone OR Caprylidene OR Carbamazepine OR Cariprazine OR Chlordiazepoxide OR Chlorpromazine OR Citalopram OR Clomipramine OR Clonazepam OR Clonidine OR Clorazepate OR Clozapine OR Cyamemazine OR Desipramine OR Desvenlafaxine OR Deutetrabenazine OR Dextromethorphan OR Diazepam OR Diphenhydramine OR Disulfiram OR Donepezil OR Dothiepin OR Doxepin OR Duloxetine OR Escitalopram OR Esketamine OR Estazolam OR Eszopiclone OR Flibanserin OR Flumazenil OR Flunitrazepam OR Fluoxetine OR Flupenthixol OR Fluphenazine OR Flurzepam OR Fluvoxamine OR Gabapentin OR Galantamine OR Fuanfacine OR Haloperidol OR Hydroxyzine OR Iloperidone OR Imipramine OR Isocarboxazid OR Ketamine OR Lamotrigine OR Lemborexant OR Levetiracetam OR Levomilnacipran OR Lisdexamfetamine OR Lithium OR Lofepramine OR Lofexidine OR Loflazepate OR Lorazepam OR Loxapine OR Lumateperone OR Lurasidone OR Maprotiline OR Memantine OR Methylfolate OR Methylphenidate OR Mianserin OR Midazolam OR Milnacipran OR Mirtazapine OR Moclobemide OR Modafinil OR Molindone OR Nalmefene OR Naltrexone OR Naltrexone/Buproprion OR Nefazodone OR Nortriptyline OR Olanzapine OR Oxazepam OR Oxcarbazepine OR Paliperidone OR Paroxetine OR Perospirone OR Perphenazine OR Phenelzine OR Phentermine/Topiramate OR Pimavanserine OR Pimozide OR Pipothiazine OR Pitolisant OR Prazosin OR Pregabalin OR Propranolol OR Protriptyline OR Quazepam OR Quetiapine OR Ramelteon OR Reboxetine OR Risperidone OR Rivastigmine OR Selegiline OR Sertindole OR Sertraline OR Sildenafil OR Sodium oxybate OR Solriamfetol OR Sulpiride OR Suvoxerant OR Tasimelteon OR Temazepam OR Thioridazine OR Thiothixene OR Tiagabine OR Tianeptine OR Topiramate OR Tranylcypromine OR Trazodone OR Triazolam OR Trifluoperazine OR Trihexyphenidyl OR Triiodothyronine OR Trimipramine OR Valbenazine OR Valproate OR Varenicline OR Venlafaxine OR Vilazodone OR Vortioxetine OR Zaleplon OR Ziprasidone OR Zolpidem OR Zonisamide OR Zopiclone OR Zotepine OR Zuclopenthixol. All terms were searched both as keywords and Medical Subject Headings (MeSH). The bibliographies of relevant (according to titles and abstracts) articles were hand-searched to provide additional references.</p></sec><sec id="sec2dot3-ijms-26-06514"><title>2.3. Study Selection and Data Collection Process</title><p>Three reviewers, F.D.V., E.C, and A.M.D., blinded to the other reviewer&#8217;s decision, evaluated the titles and abstracts of the studies to ascertain their eligibility. They verified separately that all the inclusion and exclusion criteria were met. In cases that were not apparent, the entire text of the publications was retrieved and examined. In every instance where there was a disagreement, a fourth author (G.C.) arbitrated.</p><p>The same three reviewers (F.D.V., E.C., and A.M.D.) separately retrieved data from qualifying studies, which were then cross-checked. Disputes were rectified by agreement. Articles that combined newly enrolled patients with those from prior studies were only taken into account for the latter. For mixed cohorts, the study only included patient data that satisfied our inclusion and exclusion criteria. Due to methodological heterogeneity and the variability in outcomes assessed across the included studies&#8212;ranging from clinical to endoscopic and including both direct and surrogate endpoints&#8212;we chose not to perform a meta-analysis or any formal statistical synthesis. Instead, we conducted a descriptive analysis, discussing each study individually in terms of design, methodology, and outcomes. For this reason, we did not register a review protocol on PROSPERO. We chose to report our results in four sections according to the type of drug that was administered.</p><p>We collected study references and citations in the EndNote software application version 20 (Thomson Reuters, New York, NY, USA). A data collection form was designed in Microsoft Excel 2016 (Microsoft, Redmond, WA, USA).</p></sec></sec><sec sec-type="results" id="sec3-ijms-26-06514"><title>3. Results</title><p>A total of 8513 studies (4165 on PubMed, 4071 on Web of Science and 1647 on Scopus) were identified overall using the abovementioned research strategies. A total of 103 articles were selected for the full abstract screening, and after that 22 articles were chosen for the synthesis of results, including 7 RCTs, 4 non-randomized controlled clinical trial, 6 observational studies, 5 case series/reports. All selected studies were in English. The 22 articles covered a population of 45.572 IBD patients, including CD, UC and IBD-U. All included studies utilized different assessment tools to evaluate both gastrointestinal and psychiatric outcomes, reflecting differences in research objectives and study populations. A summary of the primary outcome measures employed is provided in <xref rid="app1-ijms-26-06514" ref-type="app">Supplementary Table S1</xref>.</p><p><xref rid="app1-ijms-26-06514" ref-type="app">Supplementary Table S2</xref> summarizes the mechanisms of action, primary indications according to the Food and Drug Administration (FDA), and major gastrointestinal side effects of the main drugs included in the manuscript. Additionally, the table provides detailed insights and further information regarding the administration of these medications.</p><sec id="sec3dot1-ijms-26-06514"><title>3.1. Antidepressants</title><p>Among the 22 selected studies, 12 were centered on the investigation of antidepressant therapies, including 4 RCTs, 5 observational cohort studies and 3 case series/reports. Four out of 12 studies (33%) investigated different antidepressant drugs (SSRIs, TCAs, serotonin noradrenergic reuptake inhibitors (SNRIs), bupropion, trazodone and mirtazapine), while 2 (17%) focused on bupropion, 1 (8%) on tianeptine, 1 (8%) on venlafaxine, 1 (8%) on phenelzine, 1 (8%) on fluoxetine, 1 (8%) on duloxetine, and 1 (8%) on TCAs. Overall, SSRIs and SNRIs constituted the most frequently prescribed classes of antidepressants.</p><p>In details, two prospective and two retrospective observational studies investigated the role of several classes of antidepressant, including SSRI, SNRI, TCAs, and trazodone, on the disease course in patients affected by IBDs [<xref rid="B25-ijms-26-06514" ref-type="bibr">25</xref>]. Notably, in a prospective study of 331 IBD patients, Hall et al. observed a trend toward lower rates of escalation of medical therapy among patients receiving antidepressants at baseline, and of disease flares, hospitalization and intestinal resection rates in those with abnormal anxiety or depression scores at study entry [<xref rid="B25-ijms-26-06514" ref-type="bibr">25</xref>]. Similarly, Kristensen et al.&#8217;s retrospective population-based cohort study, encompassing 42,890 IBD patients, underscored a significantly reduced relapse rate in individuals exposed to antidepressants compared to their non-exposed counterparts, with a more pronounced effect observed in CD patients than in UC patients. Additionally, patients with no prior antidepressant usage exhibited superior disease course outcomes upon antidepressant exposure compared to non-users [<xref rid="B26-ijms-26-06514" ref-type="bibr">26</xref>]. Yanartas et al.&#8217;s prospective cohort study, involving 67 IBD patients treated with various antidepressant classes, evidenced significant improvements in hemoglobin levels and CDAI scores compared with baseline among individuals who adhered rigorously to the prescribed 6-month treatment regimen [<xref rid="B27-ijms-26-06514" ref-type="bibr">27</xref>]. Furthermore, a retrospective case&#8211;control study, including 58 IBD patients, revealed that patients receiving various antidepressant medications, particularly citalopram and fluoxetine, experienced fewer relapses and corticosteroid courses in the year after antidepressant initiation than in the year before; these findings were absent in the control group [<xref rid="B28-ijms-26-06514" ref-type="bibr">28</xref>]. Conversely, in two different surveys (2012, 2014), Mikoc-Walus et al. investigated the efficacy of several antidepressants in IBD patients concurrently undergoing treatment for depression or anxiety, revealing that 67% of patients reported no alteration in their IBD activity, 26% reported physical symptom improvement, 5% referred symptom exacerbation, and 2% attributed difficulty in distinguishing antidepressant effects from other potential causal factors [<xref rid="B29-ijms-26-06514" ref-type="bibr">29</xref>].</p><p>A randomized clinical trial (RCT) conducted by Daghaghzadeh et al. established the efficacy of duloxetine in alleviating symptom severity, as assessed by the LCAI score, in 35 individuals diagnosed with IBD [<xref rid="B30-ijms-26-06514" ref-type="bibr">30</xref>]. Meanwhile, Mikocka-Walus et al. (2017) examined the utility of fluoxetine, an SSRI, in CD patients, revealing no significant improvement of CDAI scores or fecal calprotectin levels after the treatment [<xref rid="B29-ijms-26-06514" ref-type="bibr">29</xref>]. Recently, Liang et al. conducted an RCT, exploring the therapeutic potential of venlafaxine, an SNRI, in 45 patients diagnosed with UC and CD. The study&#8217;s primary endpoints included the IBDQ score and disease activity assessments (CDAI for CD, Mayo score for UC), with secondary endpoints encompassing disease course, SES-CD, UCEIS, relapse rate, corticosteroid/biologic usage frequency, as well as pertinent laboratory parameters, including white blood cells count (WBC), albumin, C reactive protein (CRP), fecal calprotectin, erythrocyte sedimentation (ESR), tumor necrosis factor (TNF)-&#945;, and interleukin (IL)-10. Notably, IBDQ scores exhibited a significant elevation in the venlafaxine cohort compared to the placebo group. Furthermore, UC and CD patients treated with venlafaxine demonstrated reduced Mayo score and CDAI score, respectively, following the 6-month assessment period. However, the study did not discern significant disparities in UCEIS and SES-CD scores between the venlafaxine and placebo cohorts at the 6-month juncture [<xref rid="B31-ijms-26-06514" ref-type="bibr">31</xref>].</p><p>Only one retrospective cohort investigation focused on the efficacy of tricyclic antidepressants (TCAs) in ameliorating gastrointestinal symptoms in IBD patients, elucidating a noteworthy improvement in the severity scores (established Likert scales) of both UC and CD cohorts. However, UC patients presented a better response to TCA that those with CD [<xref rid="B32-ijms-26-06514" ref-type="bibr">32</xref>].</p><p>Tianeptine, an atypical antidepressant, succeeded in reducing symptoms of anxiety and depression, as well as disease activity index, in 60 patients with IBD compared with placebo after 12 months [<xref rid="B33-ijms-26-06514" ref-type="bibr">33</xref>].</p><p>Interestingly, some case reports exhibited promising effects on gastrointestinal symptoms after bupropion intake. A case series of 4 patients by Kane et al. (2003) and a case report of 2 patients by Kast and Altschuler (2001) documented the achievement of clinical remission (CDAI &lt; 150) in six patients affected by CD following bupropion administration for varied indications [<xref rid="B34-ijms-26-06514" ref-type="bibr">34</xref>,<xref rid="B35-ijms-26-06514" ref-type="bibr">35</xref>]. One patient experienced a flare-up of CD after discontinuing bupropion on her own.</p><p>Finally, in 1998, Kast et al. detailed the case of a 33-year-old woman receiving phenelzine, who experienced sustained improvement in bowel function and abdominal pain, persisting post-azathioprine and prednisone tapering, albeit experiencing CD relapse subsequent to nortriptyline transition six weeks later [<xref rid="B36-ijms-26-06514" ref-type="bibr">36</xref>].</p><p>Only a minority of the aforementioned studies specifically examined also the impact of antidepressants on psychiatric disorders in patients with IBD. A population-based study conducted by Jayasooriya (2022) revealed a higher incidence of antidepressant usage within the IBD cohort, with the greatest risk occurring during the initial year post-IBD diagnosis [<xref rid="B37-ijms-26-06514" ref-type="bibr">37</xref>]. Furthermore, among IBD patients initiating antidepressant therapy, 67% received treatment for a duration less than the recommended minimum of 7 months.</p><p>The RCT featuring duloxetine by Daghaghzadeh et al., evaluated anxiety and depression with the Hospital Anxiety and Depression Scale (HADS), while Quality of Life (QOL) was assessed via the World Health Organization Quality of Life abbreviated version (WHOQOL-BREF) [<xref rid="B30-ijms-26-06514" ref-type="bibr">30</xref>]. The findings indicated a significant reduction in anxiety and depression levels alongside an enhancement in physical, psychological, and social QOL domains, although no notable difference in environmental QOL was observed. Similarly, the randomized clinical trial conducted by Mikocka-Walus et al. (2017), involving fluoxetine, utilized the same assessment scales, yet fluoxetine exhibited negligible influence on psychological symptoms or QOL [<xref rid="B29-ijms-26-06514" ref-type="bibr">29</xref>].</p><p>HADS was further employed in an additional RCT featuring an SNRI, venlafaxine (Liang, 2022), which revealed a noteworthy reduction in HADS depression scores after the treatment [<xref rid="B31-ijms-26-06514" ref-type="bibr">31</xref>]. Additionally, a prospective cohort study [<xref rid="B27-ijms-26-06514" ref-type="bibr">27</xref>] (Yanartas, 2016), predominantly comprising SSRI recipients, reported improvements in anxiety and depression levels as measured by HAD-A and HAD-D scales, respectively, alongside enhancements in SF-36 and ASSES scores.</p><p>In two case reports by Kast and Altschuler (2001) [<xref rid="B35-ijms-26-06514" ref-type="bibr">35</xref>] and Kast (1998) [<xref rid="B36-ijms-26-06514" ref-type="bibr">36</xref>], bupropion and phenelzine exhibited efficacy in alleviating depression symptoms in patients with CD.</p><p>Data extracted from each primary study are shown in <xref rid="ijms-26-06514-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec3dot2-ijms-26-06514"><title>3.2. Antiepileptics</title><p>Only one retrospective cohort study [<xref rid="B38-ijms-26-06514" ref-type="bibr">38</xref>] focused on topiramate use in IBD patients, based on a large cohort of IBD patients: 775 were treated with topiramate and 958 were treated with other anticonvulsant and anti-migraine medications. However, there was no difference between topiramate users concerning steroid prescription, post-exposure initiation of biologic agents, abdominal surgery or hospitalization. In this study, effects on psychological symptoms were not reported.</p><p>Interestingly, one case report described a clinical, biochemical, and subsequently endoscopic (after 6 months) improvement in a patient with CD undergoing therapy with Pregabalin for psychic and physical anxiety [<xref rid="B39-ijms-26-06514" ref-type="bibr">39</xref>].</p><p>Data extracted from each primary study are shown in <xref rid="ijms-26-06514-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec3dot3-ijms-26-06514"><title>3.3. Hypnoinducers and Anxiolytics</title><p>According to a retrospective matched cohort study [<xref rid="B40-ijms-26-06514" ref-type="bibr">40</xref>] (Bernstein, 2022), the use of BZD and Z-drugs (to treat mood/anxiety disorders and sleep disorders) is more common in IBD patients than in controls. Nevertheless, all the available studies focus exclusively on psychological effects, not including gastrointestinal outcomes (Stokes, 1978) [<xref rid="B41-ijms-26-06514" ref-type="bibr">41</xref>], therefore none of them met our eligibility criteria.</p></sec><sec id="sec3dot4-ijms-26-06514"><title>3.4. Mood Stabilizers</title><p>Only one case report met our eligibility criteria, [<xref rid="B42-ijms-26-06514" ref-type="bibr">42</xref>] describing the administration of lithium carbonate in the manic phase of a 67-year-old patient with ulcerative colitis, in an active phase with recent endoscopic evidence of &#8220;severe, active ulcerative colitis, already undergoing therapy with salicosulfapiridine (azulfadine)&#8221;. After five days, there was considerable improvement in both gastrointestinal and psychiatric symptoms, and after two months, the endoscopic evidence revealed considerable improvement with only a few small bleeding spots. Data extracted from the primary study are shown in <xref rid="ijms-26-06514-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec3dot5-ijms-26-06514"><title>3.5. Others</title><p>Other studies which met our eligibility criteria investigated the role of naltrexone, clonidine and lithium on the disease course of IBD patients. A total of four trials explored the effect of naltrexone in IBD, three of them focused on CD.</p><p>Lie et al. 2018 [<xref rid="B43-ijms-26-06514" ref-type="bibr">43</xref>] evaluated low-dose naltrexone (LDN) for induction of remission in IBD patients (UC and CD) not responsive to conventional therapy. LDN induced clinical improvement in 74.5% and remission in 25.5% of patients. There was no statistically significant difference between CD and UC patients in rates of response or remission. Patients achieving clinical remission had a significantly greater improvement in endoscopic score than patients not reaching clinical response. However, 14.9% reported adverse events due to LDN (vivid dreams, drowsiness, and headache).</p><p>Smith et al. in 2011 [<xref rid="B44-ijms-26-06514" ref-type="bibr">44</xref>] in an RCT, confirmed naltrexone as a promising therapy for CD: 88% of those treated with naltrexone had at least a 70-point decline in CDAI scores compared to 40% of placebo-treated patients, and 78% of active arm had an endoscopic response (a 5-point decline in the Crohn&#8217;s disease endoscopy index severity score (CDEIS) from baseline compared to 28% response in placebo-treated controls, thereby confirming their findings previously described in 2007. In addition, in 2007, Smith et al. [<xref rid="B45-ijms-26-06514" ref-type="bibr">45</xref>] also reported an improvement in QoL compared to baseline during naltrexone therapy. Smith et al. randomized pediatric patients with CD [<xref rid="B46-ijms-26-06514" ref-type="bibr">46</xref>] to placebo or LDN in another study. Naltrexone was well tolerated without any serious adverse events, and the PCDAI (Pediatric Crohn&#8217;s Disease Activity Index) significantly decreased in the active arm, with 25% of those achieving remission. According to the Impact III survey, an improvement in QoL from baseline was reported.</p><p>Regarding clonidine, two studies have investigated the efficacy of clonidine in patients with UC based on drug-mediated reduction of overall enhancement of sympathetic disease activity. Lechin et al. [<xref rid="B47-ijms-26-06514" ref-type="bibr">47</xref>] conducted a double-blind clinical trial of UC patients with severe activity, which was randomized to treatment with prednisone, sulfasalazine, or clonidine. Comparing performance among the three groups, treatment with prednisone and treatment with clonidine were significantly more effective than sulfasalazine (<italic toggle="yes">p</italic> &lt; 0.001) for both. There were no significant differences between prednisone treatment and clonidine treatment. However, clonidine treatment induced more rapid therapeutic effects than prednisone, without significant adverse effects. Later, Furlan et al. [<xref rid="B48-ijms-26-06514" ref-type="bibr">48</xref>] tested the reduction in sympathetic activity by clonidine on clinical changes in UC. In addition to autonomic assessment (more information in table), they were randomly assigned to transdermal clonidine for eight weeks or placebo. Changes in the autonomic profile after clonidine were associated with reduced DAI score (concomitant amelioration of symptoms and endoscopic pattern). Normalization of the autonomic profile with clonidine was accompanied by improved disease and a general increase in sympathetic activity characterized by active UC.</p><p>Data extracted from each primary study are shown in <xref rid="ijms-26-06514-t004" ref-type="table">Table 4</xref>.</p></sec></sec><sec sec-type="discussion" id="sec4-ijms-26-06514"><title>4. Discussion</title><p>In Western countries, between 10 and 30% of patients with IBD take antidepressant medications; nonetheless, to date only a few studies have investigated their role in the management of IBDs [<xref rid="B50-ijms-26-06514" ref-type="bibr">50</xref>,<xref rid="B51-ijms-26-06514" ref-type="bibr">51</xref>,<xref rid="B52-ijms-26-06514" ref-type="bibr">52</xref>]. Various systematic and narrative reviews have consistently acknowledged a favorable impact of antidepressants on the general well-being of patients with IBD [<xref rid="B11-ijms-26-06514" ref-type="bibr">11</xref>,<xref rid="B13-ijms-26-06514" ref-type="bibr">13</xref>,<xref rid="B53-ijms-26-06514" ref-type="bibr">53</xref>,<xref rid="B54-ijms-26-06514" ref-type="bibr">54</xref>,<xref rid="B55-ijms-26-06514" ref-type="bibr">55</xref>]. However, these reviews underscore the constrained and low-quality evidence available, leading to the conclusion that the efficacy of antidepressants in modulating IBD activity remains indeterminate. Although our research identified very few clinical trials that could establish a causal relationship between certain medications and the physical and mental health of patients with IBD, our systematic review revealed that antidepressant use might be beneficial to the disease course in patients with CD and UC, particularly for those who did not use antidepressants before the IBD onset, or with latent subclinical symptoms of anxiety and depression [<xref rid="B26-ijms-26-06514" ref-type="bibr">26</xref>] (<xref rid="ijms-26-06514-f002" ref-type="fig">Figure 2</xref>).</p><p>To date, only four placebo-controlled trials assessing the efficacy of antidepressants in IBD have been conducted, with one of these trials being nonrandomized [<xref rid="B29-ijms-26-06514" ref-type="bibr">29</xref>,<xref rid="B30-ijms-26-06514" ref-type="bibr">30</xref>,<xref rid="B33-ijms-26-06514" ref-type="bibr">33</xref>]. Tianeptine, an atypical antidepressant, demonstrated a reduction in symptoms of anxiety and depression, as well as a decrease in disease activity index [<xref rid="B33-ijms-26-06514" ref-type="bibr">33</xref>]. Duloxetine exhibited a reduction in anxiety and depression scores, an improvement in quality of life, and a decrease in clinical disease activity indices in a cohort of IBD patients [<xref rid="B30-ijms-26-06514" ref-type="bibr">30</xref>]. Likewise, venlafaxine was shown to enhance quality of life, decrease depression scores, and reduce clinical disease activity indices (CDAI and Mayo scores) [<xref rid="B31-ijms-26-06514" ref-type="bibr">31</xref>]. Conversely, fluoxetine did not demonstrate any significant effect on anxiety, depression, quality of life, or clinical disease activity indices. Nonetheless, modest effects of fluoxetine on immune functions have been observed, including an increased proportion of effector memory T helper cells and a decreased proportion of effector memory T cytotoxic cells [<xref rid="B29-ijms-26-06514" ref-type="bibr">29</xref>]. Notably, antidepressant use in patients with IBDs has been associated with several positive outcomes according to observational studies and case reports, including lower rates of hospitalization, surgical intervention, and medical treatment escalation [<xref rid="B26-ijms-26-06514" ref-type="bibr">26</xref>]. Smaller studies corroborated these findings [<xref rid="B34-ijms-26-06514" ref-type="bibr">34</xref>,<xref rid="B37-ijms-26-06514" ref-type="bibr">37</xref>], showing reduced medical therapy escalation and fewer disease relapses among patients receiving antidepressants [<xref rid="B28-ijms-26-06514" ref-type="bibr">28</xref>], particularly in those with high baseline anxiety or depression [<xref rid="B25-ijms-26-06514" ref-type="bibr">25</xref>]. Tricyclic antidepressants specifically show a better response in ulcerative colitis compared to Crohn&#8217;s disease, and bupropion has demonstrated efficacy in inducing clinical remission in patients with Crohn&#8217;s disease [<xref rid="B32-ijms-26-06514" ref-type="bibr">32</xref>]. Furthermore, in a large epidemiological investigation encompassing over 400,000 individuals, the heightened risk of new-onset IBD observed among individuals with baseline depression appeared to be attenuated by the administration of antidepressants [<xref rid="B56-ijms-26-06514" ref-type="bibr">56</xref>].</p><p>It is well established that the vagus nerve, which is a key component of the brain&#8211;gut axis, plays a critical role in the tonic suppression of acute inflammation in IBD. Depression has been shown to disrupt this tonic vagal inhibition of pro-inflammatory cells, thereby increasing vulnerability to intestinal inflammation. Tricyclic antidepressants have been demonstrated to alleviate intestinal inflammation by restoring vagal function [<xref rid="B57-ijms-26-06514" ref-type="bibr">57</xref>]. Additional studies have reported that depression can reactivate dormant chronic colitis through a process dependent on the &#945;7 subunit of the nicotinic acetylcholine receptor (&#945;7nAChR), which is normalized following treatment with antidepressants [<xref rid="B58-ijms-26-06514" ref-type="bibr">58</xref>]. Indeed, the most intriguing potential effect of antidepressants in IBD is for the control of intestinal and systemic inflammation. A recent meta-analysis [<xref rid="B59-ijms-26-06514" ref-type="bibr">59</xref>] showed that an antidepressant treatment lowers the levels of the pro-inflammatory cytokines IL-4 and IL-6 in peripheral blood, thus resulting in an anti-inflammatory effect. The immunomodulatory mechanism of antidepressants could also be based on a shift between T helper-1 (Th1) and T helper-2 (Th2) lymphocytes cytokines production [<xref rid="B60-ijms-26-06514" ref-type="bibr">60</xref>] (<xref rid="ijms-26-06514-f003" ref-type="fig">Figure 3</xref>). In animal models of IBD, desipramine demonstrated a reduction in microscopic damage and mitigated colonic myeloperoxidase activity compared to placebo [<xref rid="B61-ijms-26-06514" ref-type="bibr">61</xref>]. Likewise, both desipramine and fluoxetine significantly decreased serum concentrations of IL-1&#946; and TNF-&#945; in an animal model (all <italic toggle="yes">p</italic> &lt; 0.001) [<xref rid="B62-ijms-26-06514" ref-type="bibr">62</xref>]. A recent study by Teng et al. showed that treatment with fluoxetine in C56BL/6 mice of the IBD model induced macrophages to M2-like phenotype and inhibited the production of Paneth cells, while enterocytes, goblet cells and stem cells became the dominating cells, thereby exerting a protective effect on IBD [<xref rid="B63-ijms-26-06514" ref-type="bibr">63</xref>]. As is widely known, the main target of fluoxetine is the 5-HT transporter (SERT), which blocks reuptake and prolongs neurotransmitter signaling of 5-HT [<xref rid="B64-ijms-26-06514" ref-type="bibr">64</xref>]. Previous data suggest that SERT inhibition may exert a systemic immunosuppressive effect, partly through stimulation of M2 macrophage polarization. Another SSRI, sertraline, has been shown to inhibit the activation of Toll-like receptor (TLR)-3, thereby interfering with innate immunity [<xref rid="B65-ijms-26-06514" ref-type="bibr">65</xref>]. Moreover, SSRIs seem to block the activation and proliferation of antigen presenting cells, thus influencing adaptive immunity [<xref rid="B66-ijms-26-06514" ref-type="bibr">66</xref>]. Similarly, preclinical in vivo studies suggested a potential immunosuppressive effect for SNRIs, reducing the generation of pro-inflammatory cytokines, such as TNF-&#945;, IFN-gamma, and IL-12 [<xref rid="B67-ijms-26-06514" ref-type="bibr">67</xref>]. However, in studies on humans and healthy volunteers, venlafaxine and duloxetine presented inconsistent and minor effects on cytokines, lymphocyte subpopulations or circulating levels of neurotrophic factors [<xref rid="B68-ijms-26-06514" ref-type="bibr">68</xref>,<xref rid="B69-ijms-26-06514" ref-type="bibr">69</xref>,<xref rid="B70-ijms-26-06514" ref-type="bibr">70</xref>]. These findings collectively suggest that the use of antidepressants should be considered in patients with IBD, not only for managing subclinical or mild symptoms of anxiety and depression&#8212;often underestimated and underdiagnosed&#8212;but also for potentially modulating the disease course and improving clinical outcomes in selected patients. Although studies investigating the kynurenine pathway of tryptophan degradation in IBD are lacking, the previous literature suggested that depression linked with chronic inflammatory disorders, such as cancer, might have a distinct etiology compared to other forms of depression [<xref rid="B71-ijms-26-06514" ref-type="bibr">71</xref>,<xref rid="B72-ijms-26-06514" ref-type="bibr">72</xref>]. Notably, alterations in the kynurenine pathway due to inflammation, interfering with the bioavailability of tryptophan, necessary for the synthesis of serotonin, may play a crucial role in the development and persistence of both conditions [<xref rid="B71-ijms-26-06514" ref-type="bibr">71</xref>,<xref rid="B72-ijms-26-06514" ref-type="bibr">72</xref>].</p><p>Hence, targeting enzymes implicated in the kynurenine pathway could present a dual therapeutic opportunity for treating both IBD (or other inflammatory conditions) and depression concurrently [<xref rid="B73-ijms-26-06514" ref-type="bibr">73</xref>]. In this scenario, antidepressants may potentially facilitate this approach [<xref rid="B74-ijms-26-06514" ref-type="bibr">74</xref>].</p><p>Additionally, antidepressants may exert their anti-inflammatory effects through the modulation of intestinal microbiota composition [<xref rid="B75-ijms-26-06514" ref-type="bibr">75</xref>]. Fluoxetine increases the abundance of certain taxa such as phylum Bacteroidetes, family Porphyromonadaceae, and genera Parabacteroides, Butyricimonas, and Alistipes. It decreases the abundance of phylum Firmicutes, as well as taxa like Ruminococcus and Adlercreutzia [<xref rid="B76-ijms-26-06514" ref-type="bibr">76</xref>,<xref rid="B77-ijms-26-06514" ref-type="bibr">77</xref>]. Escitalopram reduces the abundance of Ruminococcus and Adlercreutzia [<xref rid="B76-ijms-26-06514" ref-type="bibr">76</xref>]. Venlafaxine and duloxetine also decrease the abundance of Ruminococcus and Adlercreutzia [<xref rid="B76-ijms-26-06514" ref-type="bibr">76</xref>]. Amitriptyline, on the other hand, boosts the abundance of phylum Bacteroidetes, family Porphyromonadaceae, family Bacteroidaceae, and genera Parabacteroides, Butyricimonas, and Alistipes, while reducing the abundance of phylum Firmicutes [<xref rid="B77-ijms-26-06514" ref-type="bibr">77</xref>]. Ketamine increases the abundance of bacterial genera such as Lactobacillus, Turicibacter, and Sarcina, while decreasing the abundance of opportunistic pathogens like Ruminococcus and Mucispirallum [<xref rid="B78-ijms-26-06514" ref-type="bibr">78</xref>].</p><p>Another important role of antidepressants is in the treatment of chronic pain. In a recent meta-analysis [<xref rid="B79-ijms-26-06514" ref-type="bibr">79</xref>], duloxetine was found to be the most effective antidepressant for managing chronic pain. There are also studies supporting the efficacy of milnacipran in treating chronic pain, but these studies are significantly fewer and of lower quality compared to those on duloxetine. The mechanism involves noradrenaline reuptake inhibition, which enhances analgesic effects mainly through &#945;2-adrenergic receptors in the dorsal horn of the spinal cord [<xref rid="B80-ijms-26-06514" ref-type="bibr">80</xref>]. Therefore, duloxetine might be a viable candidate for conditions involving chronic pain (such as IBD) and low mood.</p><p>A recent and intriguing meta-analysis demonstrated that antidepressants are safe and effective in treating depression comorbid with medical conditions. Additionally, the meta-analysis highlighted the ability of antidepressants to prevent depression [<xref rid="B81-ijms-26-06514" ref-type="bibr">81</xref>]. Given the high prevalence of depression among individuals with IBD, it might be beneficial to consider low-dose antidepressants for those with a history of depressive episodes or even mild alterations on baseline psychometric scales for depression. Ultimately, the decision should depend on the clinical judgment of the physician, preferably with a psychiatrist&#8217;s consultation.</p><p>Despite various gastrointestinal side effects reported in the literature due to antidepressant therapy, particularly with escitalopram and sertraline, which seem to be less tolerated by the gastrointestinal tract [<xref rid="B82-ijms-26-06514" ref-type="bibr">82</xref>], researchers are increasingly interested in understanding the role of antidepressants, specifically serotonin reuptake inhibitors, in functional gastrointestinal disorders like irritable bowel syndrome (IBS). Considering that IBD can cause issues with intestinal motility leading to constipation and bloating, and to the overlap between IBD and IBS [<xref rid="B83-ijms-26-06514" ref-type="bibr">83</xref>], antidepressants may prove beneficial in managing these conditions. Notably, in a randomized controlled trial by Tack et al., it is reported that citalopram can increase colonic contractility and the occurrence of high-amplitude propagated contractions, together with an increased colonic compliance during fasting, suppressing the postprandial colonic tone [<xref rid="B84-ijms-26-06514" ref-type="bibr">84</xref>].</p><p>Additionally, antidepressants (along with other pharmacological classes) can be used in managing psychiatric side effects associated with corticosteroid therapy [<xref rid="B85-ijms-26-06514" ref-type="bibr">85</xref>], which is widely used in the management of IBD [<xref rid="B86-ijms-26-06514" ref-type="bibr">86</xref>]. Symptoms seem to vary according to the corticosteroid dosage and typically emerge within the initial weeks of treatment. Unfortunately, there is a lack of knowledge regarding the risk factors associated with the onset of mood instability [<xref rid="B87-ijms-26-06514" ref-type="bibr">87</xref>].</p><p>Another promising molecule that has been investigated in patients with IBD is naltrexone. The rationale for its use as a treatment in IBD is based on the relevance of the endogenous opioid system in gut immunity [<xref rid="B88-ijms-26-06514" ref-type="bibr">88</xref>,<xref rid="B89-ijms-26-06514" ref-type="bibr">89</xref>]. Indeed, in IBD patients, the &#956;-opioid receptor (MOR) is overexpressed in mucosal T-lymphocytes and monocytes, and the administration of low dose Naltrexone (LDN) would appear to upregulate the endogenous encephalin and endorphin levels and to have a positive modulatory effect on the MOR [<xref rid="B90-ijms-26-06514" ref-type="bibr">90</xref>].</p><p>Additionally, it has been shown that the opioid inactive (+)-isomers of naltrexone inhibit lipopolysaccharide-induced Toll-like Receptor 4 (TLR4) signaling, a bacterial-induced inflammatory pathway contributing to IBD [<xref rid="B91-ijms-26-06514" ref-type="bibr">91</xref>,<xref rid="B92-ijms-26-06514" ref-type="bibr">92</xref>].</p><p>Furthermore, the effects of such therapy could also be expressed on the reduction in endoplasmic reticulum (ER) stress in intestinal Paneth cells, which is one of the contributing factors in IBD [<xref rid="B93-ijms-26-06514" ref-type="bibr">93</xref>,<xref rid="B94-ijms-26-06514" ref-type="bibr">94</xref>,<xref rid="B95-ijms-26-06514" ref-type="bibr">95</xref>].</p><p>In the studies analyzed, naltrexone therapy was associated with favorable clinical response rates, clinical remission, and endoscopic response (endoscopic scores improved by 48% compared to baseline, <italic toggle="yes">p</italic> = 0.018) [<xref rid="B44-ijms-26-06514" ref-type="bibr">44</xref>]. Naltrexone also showed good tolerance in the pediatric population with CD. However, these results were obtained from cohorts with a relatively small number of participants over a limited observation period. Although most of the studies are conducted on CD, it is not entirely clear whether this therapy may also be helpful in UC patients (only one study is available) or whether there are any subclasses of patients in which it may be more effective. A multicenter study by Paulides et al. with a more significant number of patients for a longer observation time is still ongoing [<xref rid="B43-ijms-26-06514" ref-type="bibr">43</xref>].</p><p>In the literature, there are no studies evaluating how naltrexone can induce changes in the gut microbiota. However, there is evidence showing that naltrexone can improve inflammatory parameters in a murine model of enteritis [<xref rid="B96-ijms-26-06514" ref-type="bibr">96</xref>].</p><p>From a psychiatric perspective, naltrexone can also enhance positive emotional states by boosting the effects of endogenous opioids, leading to increased positive feelings and energy [<xref rid="B97-ijms-26-06514" ref-type="bibr">97</xref>]. A review by Brown and Panksepp suggests that low doses of naltrexone may also play a role in promoting stress resilience, exercise, social bonding, and emotional well-being, as well as improving psychiatric conditions such as autism and depression [<xref rid="B98-ijms-26-06514" ref-type="bibr">98</xref>].</p><p>Clonidine, by activating the alpha-2 adrenergic receptors in the brainstem, inhibits the release of norepinephrine, a neurotransmitter that typically stimulates the sympathetic nervous system. The rationale for its utilization is based on the role of the cholinergic anti-inflammatory pathway (CAIP) on the potential anti-inflammatory effect on immune cells in animal models [<xref rid="B99-ijms-26-06514" ref-type="bibr">99</xref>]. Experimental activation of CAIP inhibits TNF synthesis in the liver, spleen and heart, attenuating serum TNF concentrations during endotoxemia by LPS [<xref rid="B100-ijms-26-06514" ref-type="bibr">100</xref>]. Furthermore, an overall increased sympathetic activity would seem to support the inflammatory process of UC, which can also be inferred from the fact that psychological stress can reactivate quiescent UC. On the other hand, increasing para-sympathetic organ drive using a nicotine patch has been shown to improve the inflammatory state in patients with UC [<xref rid="B101-ijms-26-06514" ref-type="bibr">101</xref>].</p><p>However, as previously described, studies investigating clonidine administration in patients with ulcerative colitis are limited. Lechin et al. in 1985 observed a clinical and endoscopic improvement with clonidine treatment, and it was significantly more effective when compared to sulfasalazine, while there were no significant differences between prednisone and clonidine treatment [<xref rid="B47-ijms-26-06514" ref-type="bibr">47</xref>].</p><p>Later, although they stated that their investigation must not be considered a pharmacological trial, Furlan and collaborators found that clonidine reduced systemic neural sympathetic activity and increased vagal cardiac modulation, which was associated with decreased DAI, indicated by amelioration of clinical symptoms and colon endoscopic pattern. However, several crucial variables, including smoking status, previous UC therapy, and gender, were documented but not individually examined, likely due to the limited size of the sample. The researchers did not specify whether a post hoc test was conducted during the statistical analysis. Even in this case, the number of patients treated, and the observation time are limited, so future more extensive studies are needed to aim for such an alternative or combined therapy for future clinical practice in IBD [<xref rid="B48-ijms-26-06514" ref-type="bibr">48</xref>]. Notably, no significant hypotensive effects were reported during treatment in these studies.</p><p>Conversely, for drugs such as pregabalin and lithium carbonate, the precise mechanisms by which they may influence intestinal inflammation in IBD remain largely unclear. However, some preclinical data provide mechanistic insights. In a murine model of acetic acid-induced colitis, pregabalin reduced both macroscopic and microscopic intestinal damage and inflammation, decreasing colonic levels of TNF-&#945;, IL-6, IL-1&#946;, and myeloperoxidase (MPO) activity [DOI: 10.4103/1735-5362.329924]. Pregabalin appears to exert its effects via modulation of the glutamate/N-methyl-D-aspartate receptor (NMDA)&#8211;nuclear factor kappa B (NF-&#954;B)&#8211;cyclooxygenase-2 (COX-2) signaling axis, leading to reduced cytokine secretion and neutrophil infiltration. Additionally, pregabalin may attenuate neurogenic inflammation through interaction with the alpha-2-delta (&#945;2&#948;) subunits of voltage-gated calcium channels. In sensitized animal models, it has been shown to reduce accelerated defecation and increase the colonic nociceptive threshold, indicating a role in visceral pain modulation [<xref rid="B102-ijms-26-06514" ref-type="bibr">102</xref>].</p><p>Regarding lithium, it has been shown to inhibit glycogen synthase kinase-3 beta (GSK-3&#946;), activate the wingless-related integration site/beta-catenin (Wnt/&#946;-catenin) signaling pathway. This activity promotes epithelial regeneration and downregulates key inflammatory mediators such as COX-2, TNF-&#945;, and IL-1&#946;.</p><p>Accordingly, in dextran sulfate sodium (DSS)-induced colitis models, lithium carbonate also promoted the activation of regulatory T lymphocytes (Tregs) via the G-protein-coupled receptor 43 (GPR43), contributing to the attenuation of intestinal inflammation [<xref rid="B103-ijms-26-06514" ref-type="bibr">103</xref>]. In summary, the beneficial effects observed with antidepressants, clonidine, and naltrexone likely reflect their shared ability to modulate both central and peripheral inflammatory pathways. Antidepressants exert anti-inflammatory actions via cytokine suppression, vagal tone enhancement, and microbiota modulation. Naltrexone acts through &#956;-opioid receptor blockade and TLR4 inhibition, while clonidine reduces sympathetic activity and activates the cholinergic anti-inflammatory pathway. In contrast, agents like topiramate lack such immunomodulatory properties, and pregabalin or lithium although promising are supported only by limited preclinical evidence.</p></sec><sec id="sec5-ijms-26-06514"><title>5. Strengths and Limitations</title><p>A key strength of our systematic review lies in its global perspective, achieved through an extensive and comprehensive literature search that included studies conducted across multiple countries and over an extended time frame. Notably, this is the first systematic effort to compile all available evidence, including case series and case reports, on the efficacy of psychiatric medications in managing gastrointestinal symptoms, as well as both direct and surrogate markers of disease activity in IBD.</p><p>However, our review has certain limitations that should be acknowledged. The studies included encompass a wide range of designs&#8212;randomized and nonrandomized controlled trials, observational studies (both prospective and retrospective), case series, and case reports&#8212;which exhibit significant heterogeneity in study design, study population, intervention, definition of outcome and in the modality of outcome measurement. This heterogeneity precluded the possibility of performing a meta-analysis, limited the statistical power and impaired the overall level of evidence derived from this review.</p></sec><sec sec-type="conclusions" id="sec6-ijms-26-06514"><title>6. Conclusions</title><p>This systematic review demonstrates the potential of several classes of psychiatric medications to improve both gastroenterological outcomes, such as inflammation and disease activity, and psychological well-being in IBD. Antidepressants, including bupropion, TCAs, SSRIs, venlafaxine, and duloxetine, have been consistently associated with improvements in both direct and surrogate markers of disease activity. While case reports suggest potential benefits from pregabalin and lithium carbonate, no improvement in disease activity has been observed with topiramate. Moreover, some RCTs have reported positive outcomes with clonidine and naltrexone in both UC and CD.</p><p>Our review also highlights the mechanisms of these psychotropic drugs that extend beyond the &#8220;simple&#8221; neurochemical modulation within the central nervous system, also contributing to an anti-inflammatory action, which may in the future allow their use as adjuvant anti-inflammatory therapies. These findings suggest that a holistic approach, integrating psychiatry with other medical disciplines in IBD care, holds promise for improving disease activity, clinical and surgical outcomes, and quality of life in IBD patients. However, further robust RCTs with larger sample sizes and standardized outcome measures, along with translational research, are necessary to evaluate whether psychiatric medications with well-established safety profiles could serve as adjuvant treatments in IBD management or function as anti-inflammatory and immunomodulatory agents.</p></sec></body><back><ack><title>Acknowledgments</title><p>Thanks to Fondazione Roma for continuous support for our scientific research.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijms-26-06514"><title>Supplementary Materials</title><p>The supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ijms26136514/s1">https://www.mdpi.com/article/10.3390/ijms26136514/s1</uri>. References [<xref rid="B104-ijms-26-06514" ref-type="bibr">104</xref>,<xref rid="B105-ijms-26-06514" ref-type="bibr">105</xref>,<xref rid="B106-ijms-26-06514" ref-type="bibr">106</xref>,<xref rid="B107-ijms-26-06514" ref-type="bibr">107</xref>,<xref rid="B108-ijms-26-06514" ref-type="bibr">108</xref>,<xref rid="B109-ijms-26-06514" ref-type="bibr">109</xref>,<xref rid="B110-ijms-26-06514" ref-type="bibr">110</xref>,<xref rid="B111-ijms-26-06514" ref-type="bibr">111</xref>,<xref rid="B112-ijms-26-06514" ref-type="bibr">112</xref>,<xref rid="B113-ijms-26-06514" ref-type="bibr">113</xref>,<xref rid="B114-ijms-26-06514" ref-type="bibr">114</xref>,<xref rid="B115-ijms-26-06514" ref-type="bibr">115</xref>,<xref rid="B116-ijms-26-06514" ref-type="bibr">116</xref>,<xref rid="B117-ijms-26-06514" ref-type="bibr">117</xref>,<xref rid="B118-ijms-26-06514" ref-type="bibr">118</xref>,<xref rid="B119-ijms-26-06514" ref-type="bibr">119</xref>,<xref rid="B120-ijms-26-06514" ref-type="bibr">120</xref>] are cited in the supplementary materials.</p><supplementary-material id="ijms-26-06514-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ijms-26-06514-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, F.D.V. and A.M.D.; methodology, F.D.V.; validation, A.D.G., E.C., and A.M.D.; formal analysis, G.F.F. and F.P.; investigation, A.S., M.M.; resources, G.D.K., M.P., and G.M.; data curation, E.C.; writing&#8212;original draft preparation, F.D.V.; writing&#8212;review and editing, G.M., A.D.G., and F.P.; visualization, L.R.L.; supervision, A.G., G.S., G.F., F.S., and G.C.; project administration, F.D.V. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>This systematic review is based on publicly available data from previously published studies. All data used in this review are accessible through the cited articles and their respective publishers. No new data were generated for this study.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-26-06514"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodhand</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Wahed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mawdsley</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rampton</surname><given-names>D.S.</given-names></name></person-group><article-title>Mood disorders in inflammatory bowel disease: Relation to diagnosis, disease activity, perceived stress, and other factors</article-title><source>Inflamm. Bowel. Dis.</source><year>2012</year><volume>18</volume><fpage>2301</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1002/ibd.22916</pub-id><pub-id pub-id-type="pmid">22359369</pub-id></element-citation></ref><ref id="B2-ijms-26-06514"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roderburg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yaqubi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Konrad</surname><given-names>M.</given-names></name><name name-style="western"><surname>May</surname><given-names>P.</given-names></name><name name-style="western"><surname>Luedde</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kostev</surname><given-names>K.</given-names></name><name name-style="western"><surname>Loosen</surname><given-names>S.H.</given-names></name></person-group><article-title>Association between inflammatory bowel disease and subsequent depression or anxiety disorders&#8212;A retrospective cohort study of 31,728 outpatients</article-title><source>J. Psychiatr. Res.</source><year>2024</year><volume>169</volume><fpage>231</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2023.11.026</pub-id><pub-id pub-id-type="pmid">38048672</pub-id></element-citation></ref><ref id="B3-ijms-26-06514"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Fisk</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Dolovich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hitchon</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Graff</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>El-Gabalawy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lix</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Patten</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Marrie</surname><given-names>R.A.</given-names></name></person-group><article-title>Understanding Predictors of Fatigue Over Time in Persons With Inflammatory Bowel Disease: The Importance of Depressive and Anxiety Symptoms</article-title><source>Am. J. Gastroenterol.</source><year>2024</year><volume>119</volume><fpage>922</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000002630</pub-id><pub-id pub-id-type="pmid">38088416</pub-id></element-citation></ref><ref id="B4-ijms-26-06514"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuendorf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Harding</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stello</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hanes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wahbeh</surname><given-names>H.</given-names></name></person-group><article-title>Depression and anxiety in patients with Inflammatory Bowel Disease: A systematic review</article-title><source>J. Psychosom. Res.</source><year>2016</year><volume>87</volume><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychores.2016.06.001</pub-id><pub-id pub-id-type="pmid">27411754</pub-id></element-citation></ref><ref id="B5-ijms-26-06514"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barberio</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zamani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Black</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Savarino</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>A.C.</given-names></name></person-group><article-title>Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: A systematic review and meta-analysis</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2021</year><volume>6</volume><fpage>359</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(21)00014-5</pub-id><pub-id pub-id-type="pmid">33721557</pub-id></element-citation></ref><ref id="B6-ijms-26-06514"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maunder</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Levenstein</surname><given-names>S.</given-names></name></person-group><article-title>The role of stress in the development and clinical course of inflammatory bowel disease: Epidemiological evidence</article-title><source>Curr. Mol. Med.</source><year>2008</year><volume>8</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.2174/156652408784533832</pub-id><pub-id pub-id-type="pmid">18537632</pub-id></element-citation></ref><ref id="B7-ijms-26-06514"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fairbrass</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Lovatt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barberio</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gracie</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>A.C.</given-names></name></person-group><article-title>Bidirectional brain-gut axis effects influence mood and prognosis in IBD: A systematic review and meta-analysis</article-title><source>Gut</source><year>2022</year><volume>71</volume><fpage>1773</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-325985</pub-id><pub-id pub-id-type="pmid">34725197</pub-id></element-citation></ref><ref id="B8-ijms-26-06514"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marrie</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Shafer</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Graff</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Patten</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>El-Gabalawy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sareen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Fisk</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>C.N.</given-names></name></person-group><article-title>Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review</article-title><source>Crohn&#8217;s Colitis 360</source><year>2020</year><volume>2</volume><fpage>otz053</fpage><pub-id pub-id-type="doi">10.1093/crocol/otz053</pub-id><pub-id pub-id-type="pmid">32003760</pub-id><pub-id pub-id-type="pmcid">PMC6977711</pub-id></element-citation></ref><ref id="B9-ijms-26-06514"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menichetti</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fiorino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vegni</surname><given-names>E.</given-names></name></person-group><article-title>Personalizing Psychological Treatment Along the IBD Journey: From Diagnosis to Surgery</article-title><source>Curr. Drug Targets</source><year>2018</year><volume>19</volume><fpage>722</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.2174/1389450118666170502142939</pub-id><pub-id pub-id-type="pmid">28464774</pub-id></element-citation></ref><ref id="B10-ijms-26-06514"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Kappelman</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Van Meter</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>S.F.</given-names></name></person-group><article-title>The burden of comedication among patients with inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2013</year><volume>19</volume><fpage>2725</fpage><lpage>2736</lpage><pub-id pub-id-type="doi">10.1097/01.MIB.0000435442.07237.a4</pub-id><pub-id pub-id-type="pmid">24216689</pub-id></element-citation></ref><ref id="B11-ijms-26-06514"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorkelson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bielefeldt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Szigethy</surname><given-names>E.</given-names></name></person-group><article-title>Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD</article-title><source>Inflamm. Bowel Dis.</source><year>2016</year><volume>22</volume><fpage>1509</fpage><lpage>1522</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000734</pub-id><pub-id pub-id-type="pmid">27167571</pub-id></element-citation></ref><ref id="B12-ijms-26-06514"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikocka-Walus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>J.M.</given-names></name></person-group><article-title>Attitudes towards antidepressants among people living with inflammatory bowel disease: An online Australia-wide survey</article-title><source>J. Crohn&#8217;s Colitis</source><year>2014</year><volume>8</volume><fpage>296</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.crohns.2013.09.002</pub-id><pub-id pub-id-type="pmid">24074632</pub-id></element-citation></ref><ref id="B13-ijms-26-06514"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarricone</surname><given-names>I.</given-names></name><name name-style="western"><surname>Regazzi</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Bonucci</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rizzello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Muratori</surname><given-names>R.</given-names></name><name name-style="western"><surname>Poggioli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Campieri</surname><given-names>M.</given-names></name><collab>EspriMici Study Group</collab></person-group><article-title>Prevalence and effectiveness of psychiatric treatments for patients with IBD: A systematic literature review</article-title><source>J. Psychosom. Res.</source><year>2017</year><volume>101</volume><fpage>68</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychores.2017.07.001</pub-id><pub-id pub-id-type="pmid">28867427</pub-id></element-citation></ref><ref id="B14-ijms-26-06514"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moher</surname><given-names>D.</given-names></name></person-group><article-title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement</article-title><source>Ann. Intern. Med.</source><year>2009</year><volume>151</volume><fpage>264</fpage><pub-id pub-id-type="doi">10.7326/0003-4819-151-4-200908180-00135</pub-id><pub-id pub-id-type="pmid">19622511</pub-id></element-citation></ref><ref id="B15-ijms-26-06514"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hayward</surname><given-names>R.S.</given-names></name></person-group><article-title>The well-built clinical question: A key to evidence-based decisions</article-title><source>ACP J. Club</source><year>1995</year><volume>123</volume><fpage>A12</fpage><pub-id pub-id-type="doi">10.7326/ACPJC-1995-123-3-A12</pub-id><pub-id pub-id-type="pmid">7582737</pub-id></element-citation></ref><ref id="B16-ijms-26-06514"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.-M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Paik</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.J.</given-names></name></person-group><article-title>Correlation between Histological Activity and Endoscopic, Clinical, and Serologic Activities in Patients with Ulcerative Colitis</article-title><source>Gastroenterol. Res. Pract.</source><year>2016</year><volume>2016</volume><fpage>32051</fpage><pub-id pub-id-type="doi">10.1155/2016/5832051</pub-id><pub-id pub-id-type="pmcid">PMC4709652</pub-id><pub-id pub-id-type="pmid">26839541</pub-id></element-citation></ref><ref id="B17-ijms-26-06514"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermeire</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sandborn</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rutgeerts</surname><given-names>P.</given-names></name></person-group><article-title>Correlation Between the Crohn&#8217;s Disease Activity and Harvey&#8211;Bradshaw Indices in Assessing Crohn&#8217;s Disease Severity</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2010</year><volume>8</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2010.01.001</pub-id><pub-id pub-id-type="pmid">20096379</pub-id></element-citation></ref><ref id="B18-ijms-26-06514"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Best</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Becktel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Singleton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>F.</given-names></name></person-group><article-title>Development of a Crohn&#8217;s disease activity index. National Cooperative Crohn&#8217;s Disease Study</article-title><source>Gastroenterology</source><year>1976</year><volume>70</volume><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(76)80163-1</pub-id><pub-id pub-id-type="pmid">1248701</pub-id></element-citation></ref><ref id="B19-ijms-26-06514"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarlas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bayliss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lovley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cappelleri</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Bushmakin</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>DiBonaventura</surname><given-names>M.D.</given-names></name></person-group><article-title>The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis</article-title><source>J. Patient Cent. Res. Rev.</source><year>2020</year><volume>7</volume><fpage>189</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.17294/2330-0698.1722</pub-id><pub-id pub-id-type="pmid">32377552</pub-id><pub-id pub-id-type="pmcid">PMC7197888</pub-id></element-citation></ref><ref id="B20-ijms-26-06514"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lichtiger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Present</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kornbluth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gelernt</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Galler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Michelassi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hanauer</surname><given-names>S.</given-names></name></person-group><article-title>Cyclosporine in severe ulcerative colitis refractory to steroid therapy</article-title><source>N. Engl. J. Med.</source><year>1994</year><volume>330</volume><fpage>1841</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1056/NEJM199406303302601</pub-id><pub-id pub-id-type="pmid">8196726</pub-id></element-citation></ref><ref id="B21-ijms-26-06514"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Seow</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Silverberg</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Steinhart</surname><given-names>A.H.</given-names></name></person-group><article-title>A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2009</year><volume>7</volume><fpage>1081</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2009.06.024</pub-id><pub-id pub-id-type="pmid">19577010</pub-id></element-citation></ref><ref id="B22-ijms-26-06514"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Travis</surname><given-names>S.P.L.</given-names></name><name name-style="western"><surname>Schnell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Krzeski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abreu</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Colombel</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Feagan</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Hanauer</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>L&#233;mann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lichtenstein</surname><given-names>G.R.</given-names></name><etal/></person-group><article-title>Developing an instrument to assess the endoscopic severity of ulcerative colitis: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS)</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2011-300486</pub-id><pub-id pub-id-type="pmid">21997563</pub-id><pub-id pub-id-type="pmcid">PMC3292713</pub-id></element-citation></ref><ref id="B23-ijms-26-06514"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daperno</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#8217;Haens</surname><given-names>G.</given-names></name><name name-style="western"><surname>Van Assche</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bulois</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maunoury</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sostegni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rocca</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gevers</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Development and validation of a new, simplified endoscopic activity score for Crohn&#8217;s disease: The SES-CD</article-title><source>Gastrointest. Endosc.</source><year>2004</year><volume>60</volume><fpage>505</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/S0016-5107(04)01878-4</pub-id><pub-id pub-id-type="pmid">15472670</pub-id></element-citation></ref><ref id="B24-ijms-26-06514"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ardizzone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bianchi Porro</surname><given-names>G.</given-names></name></person-group><article-title>A practical guide to the management of distal ulcerative colitis</article-title><source>Drugs</source><year>1998</year><volume>55</volume><fpage>519</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.2165/00003495-199855040-00004</pub-id><pub-id pub-id-type="pmid">9561342</pub-id></element-citation></ref><ref id="B25-ijms-26-06514"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Hamlin</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Gracie</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>A.C.</given-names></name></person-group><article-title>The Effect of Antidepressants on the Course of Inflammatory Bowel Disease</article-title><source>Can J. Gastroenterol. Hepatol.</source><year>2018</year><volume>2018</volume><fpage>2047242</fpage><pub-id pub-id-type="doi">10.1155/2018/2047242</pub-id><pub-id pub-id-type="pmid">30271765</pub-id><pub-id pub-id-type="pmcid">PMC6151237</pub-id></element-citation></ref><ref id="B26-ijms-26-06514"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kristensen</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kj&#230;rulff</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Ersb&#248;ll</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hallas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thygesen</surname><given-names>L.C.</given-names></name></person-group><article-title>The Influence of Antidepressants on the Disease Course Among Patients With Crohn&#8217;s Disease and Ulcerative Colitis&#8212;A Danish Nationwide Register&#8211;Based Cohort Study</article-title><source>Inflammatory Bowel Diseases</source><year>2019</year><volume>25</volume><fpage>886</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1093/ibd/izy367</pub-id><pub-id pub-id-type="pmid">30551218</pub-id><pub-id pub-id-type="pmcid">PMC6458526</pub-id></element-citation></ref><ref id="B27-ijms-26-06514"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanartas</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kani</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Bicakci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kilic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Banzragch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Acikel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Atug</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kuscu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Imeryuz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Akin</surname><given-names>H.</given-names></name></person-group><article-title>The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2016</year><volume>12</volume><fpage>673</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.2147/NDT.S106039</pub-id><pub-id pub-id-type="pmid">27069364</pub-id><pub-id pub-id-type="pmcid">PMC4818049</pub-id></element-citation></ref><ref id="B28-ijms-26-06514"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodhand</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Greig</surname><given-names>F.I.S.</given-names></name><name name-style="western"><surname>Koodun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wahed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langmead</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rampton</surname><given-names>D.S.</given-names></name></person-group><article-title>Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study</article-title><source>Inflamm. Bowel Dis.</source><year>2012</year><volume>18</volume><fpage>1232</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1002/ibd.21846</pub-id><pub-id pub-id-type="pmid">22234954</pub-id></element-citation></ref><ref id="B29-ijms-26-06514"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikocka-Walus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Bampton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campaniello</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mavrangelos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Esterman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>J.M.</given-names></name></person-group><article-title>Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn&#8217;s Disease: A Pilot Randomized Placebo-Controlled Trial</article-title><source>J. Crohn&#8217;s Colitis</source><year>2017</year><volume>11</volume><fpage>509</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjw165</pub-id><pub-id pub-id-type="pmid">27664274</pub-id><pub-id pub-id-type="pmcid">PMC5881791</pub-id></element-citation></ref><ref id="B30-ijms-26-06514"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daghaghzadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Naji</surname><given-names>F.</given-names></name><name name-style="western"><surname>Afshar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sharbafchi</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Feizi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maroufi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tabatabaeeyan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adibi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tavakoli</surname><given-names>H.</given-names></name></person-group><article-title>Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study</article-title><source>J. Res. Med. Sci.</source><year>2015</year><volume>20</volume><fpage>595</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.4103/1735-1995.165969</pub-id><pub-id pub-id-type="pmid">26600836</pub-id><pub-id pub-id-type="pmcid">PMC4621655</pub-id></element-citation></ref><ref id="B31-ijms-26-06514"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial</article-title><source>Front. Psychiatry</source><year>2022</year><volume>13</volume><elocation-id>880058</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2022.880058</pub-id><pub-id pub-id-type="pmid">35664492</pub-id><pub-id pub-id-type="pmcid">PMC9160994</pub-id></element-citation></ref><ref id="B32-ijms-26-06514"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iskandar</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Cassell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kanuri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gyawali</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dassopoulos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ciorba</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sayuk</surname><given-names>G.S.</given-names></name></person-group><article-title>Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease</article-title><source>J. Clin. Gastroenterol.</source><year>2014</year><volume>48</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1097/MCG.0000000000000049</pub-id><pub-id pub-id-type="pmid">24406434</pub-id><pub-id pub-id-type="pmcid">PMC4111227</pub-id></element-citation></ref><ref id="B33-ijms-26-06514"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chojnacki</surname><given-names>C.</given-names></name><name name-style="western"><surname>Walecka-Kapica</surname><given-names>E.</given-names></name><name name-style="western"><surname>Klupinska</surname><given-names>G.</given-names></name><name name-style="western"><surname>Paw&#322;owicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Florkowski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wachowska-Kelly</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chojnacki</surname><given-names>J.</given-names></name></person-group><article-title>Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission</article-title><source>Pol. Merkur. Lekarski</source><year>2011</year><volume>31</volume><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">21936344</pub-id></element-citation></ref><ref id="B34-ijms-26-06514"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Altschuler</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Kast</surname><given-names>R.E.</given-names></name></person-group><article-title>Crohn&#8217;s disease remission on bupropion</article-title><source>Gastroenterology</source><year>2003</year><volume>125</volume><fpage>1290</fpage><pub-id pub-id-type="doi">10.1016/j.gastro.2003.02.004</pub-id><pub-id pub-id-type="pmid">14552325</pub-id></element-citation></ref><ref id="B35-ijms-26-06514"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kast</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Altschuler</surname><given-names>E.L.</given-names></name></person-group><article-title>Remission of Crohn&#8217;s disease on bupropion</article-title><source>Gastroenterology</source><year>2001</year><volume>121</volume><fpage>1260</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1053/gast.2001.29467</pub-id><pub-id pub-id-type="pmid">11706830</pub-id></element-citation></ref><ref id="B36-ijms-26-06514"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kast</surname><given-names>R.E.</given-names></name></person-group><article-title>Crohn&#8217;s disease remission with phenelzine treatment</article-title><source>Gastroenterology</source><year>1998</year><volume>115</volume><fpage>1034</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(98)70292-6</pub-id><pub-id pub-id-type="pmid">9786733</pub-id></element-citation></ref><ref id="B37-ijms-26-06514"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayasooriya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bottle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Creese</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hotopf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pollok</surname><given-names>R.C.G.</given-names></name><collab>POP-IBD study group</collab></person-group><article-title>Antidepressant medication use in Inflammatory Bowel Disease: A nationally representative population-based study</article-title><source>Aliment. Pharmacol. Ther.</source><year>2022</year><volume>55</volume><fpage>1330</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1111/apt.16820</pub-id><pub-id pub-id-type="pmid">35244961</pub-id><pub-id pub-id-type="pmcid">PMC9311162</pub-id></element-citation></ref><ref id="B38-ijms-26-06514"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crockett</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Schectman</surname><given-names>R.</given-names></name><name name-style="western"><surname>St&#252;rmer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kappelman</surname><given-names>M.D.</given-names></name></person-group><article-title>Topiramate use does not reduce flares of inflammatory bowel disease</article-title><source>Dig. Dis. Sci.</source><year>2014</year><volume>59</volume><fpage>1535</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.1007/s10620-014-3040-7</pub-id><pub-id pub-id-type="pmid">24504592</pub-id><pub-id pub-id-type="pmcid">PMC4071112</pub-id></element-citation></ref><ref id="B39-ijms-26-06514"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Onofrio</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Di Vincenzo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferrajoli</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Scaldaferri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Camardese</surname><given-names>G.</given-names></name></person-group><article-title>Low Dose Pregabalin Improves Gastrointestinal Symptoms of Crohn&#8217;s Disease</article-title><source>Case Rep. Gastrointest. Med.</source><year>2024</year><volume>2024</volume><fpage>3744500</fpage><pub-id pub-id-type="doi">10.1155/2024/3744500</pub-id><pub-id pub-id-type="pmid">38524665</pub-id><pub-id pub-id-type="pmcid">PMC10959577</pub-id></element-citation></ref><ref id="B40-ijms-26-06514"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Fisk</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Walld</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sareen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Patten</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lix</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Hitchon</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>El-Gabalawy</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Use of Benzodiazepines and Z-Drugs in Inflammatory Bowel Disease</article-title><source>Am. J. Gastroenterol.</source><year>2022</year><volume>117</volume><fpage>2046</fpage><lpage>2054</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000001955</pub-id><pub-id pub-id-type="pmid">36288107</pub-id></element-citation></ref><ref id="B41-ijms-26-06514"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stokes</surname><given-names>D.K.</given-names></name></person-group><article-title>Lorazepam in anxiety associated with chronic enteritis and ulcerative colitis</article-title><source>J. Clin. Psychiatry</source><year>1978</year><volume>39</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">30769</pub-id></element-citation></ref><ref id="B42-ijms-26-06514"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zisook</surname><given-names>S.</given-names></name></person-group><article-title>Ulcerative colitis: Case responding to treatment with lithium carbonate</article-title><source>JAMA</source><year>1972</year><volume>219</volume><fpage>755</fpage><pub-id pub-id-type="doi">10.1001/jama.1972.03190320055024</pub-id><pub-id pub-id-type="pmid">5066706</pub-id></element-citation></ref><ref id="B43-ijms-26-06514"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lie</surname><given-names>M.R.K.L.</given-names></name><name name-style="western"><surname>Van Der Giessen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fuhler</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>de Lima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peppelenbosch</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Van Der Ent</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van Der Woude</surname><given-names>C.J.</given-names></name></person-group><article-title>Low dose Naltrexone for induction of remission in inflammatory bowel disease patients</article-title><source>J. Transl. Med.</source><year>2018</year><volume>16</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/s12967-018-1427-5</pub-id><pub-id pub-id-type="pmid">29523156</pub-id><pub-id pub-id-type="pmcid">PMC5845217</pub-id></element-citation></ref><ref id="B44-ijms-26-06514"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Bingaman</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Ruggiero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mauger</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Zagon</surname><given-names>I.S.</given-names></name></person-group><article-title>Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn&#8217;s Disease: A Randomized Placebo-Controlled Trial</article-title><source>Dig. Dis. Sci.</source><year>2011</year><volume>56</volume><fpage>2088</fpage><lpage>2097</lpage><pub-id pub-id-type="doi">10.1007/s10620-011-1653-7</pub-id><pub-id pub-id-type="pmid">21380937</pub-id><pub-id pub-id-type="pmcid">PMC3381945</pub-id></element-citation></ref><ref id="B45-ijms-26-06514"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Stock</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bingaman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mauger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rogosnitzky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zagon</surname><given-names>I.S.</given-names></name></person-group><article-title>Low-dose naltrexone therapy improves active Crohn&#8217;s disease</article-title><source>Am. J. Gastroenterol.</source><year>2007</year><volume>102</volume><fpage>820</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01045.x</pub-id><pub-id pub-id-type="pmid">17222320</pub-id></element-citation></ref><ref id="B46-ijms-26-06514"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Field</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bingaman</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mauger</surname><given-names>D.T.</given-names></name></person-group><article-title>Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn&#8217;s disease: A pilot study</article-title><source>J. Clin. Gastroenterol.</source><year>2013</year><volume>47</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1097/MCG.0b013e3182702f2b</pub-id><pub-id pub-id-type="pmid">23188075</pub-id><pub-id pub-id-type="pmcid">PMC3586944</pub-id></element-citation></ref><ref id="B47-ijms-26-06514"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lechin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Van Der Dijs</surname><given-names>B.</given-names></name><name name-style="western"><surname>Insausti</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Villa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lechin</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Arocha</surname><given-names>L.</given-names></name><name name-style="western"><surname>Oramas</surname><given-names>O.</given-names></name></person-group><article-title>Treatment of Ulcerative Colitis With Clonidine</article-title><source>J. Clin. Pharma</source><year>1985</year><volume>25</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1985.tb02828.x</pub-id><pub-id pub-id-type="pmid">2860133</pub-id></element-citation></ref><ref id="B48-ijms-26-06514"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furlan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ardizzone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palazzolo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rimoldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perego</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barbic</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bevilacqua</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vago</surname><given-names>L.</given-names></name><name name-style="western"><surname>Porro</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Malliani</surname><given-names>A.</given-names></name></person-group><article-title>Sympathetic overactivity in active ulcerative colitis: Effects of clonidine</article-title><source>Am. J. Physiol.-Regul. Integr. Comp. Physiol.</source><year>2006</year><volume>290</volume><fpage>R224</fpage><lpage>R232</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00442.2005</pub-id><pub-id pub-id-type="pmid">16123227</pub-id></element-citation></ref><ref id="B49-ijms-26-06514"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulides</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lie</surname><given-names>M.R.K.L.</given-names></name><name name-style="western"><surname>Van Der Woude</surname><given-names>C.J.</given-names></name></person-group><article-title>Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn&#8217;s disease: Protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><fpage>e058358</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2021-058358</pub-id><pub-id pub-id-type="pmcid">PMC8996009</pub-id><pub-id pub-id-type="pmid">35396307</pub-id></element-citation></ref><ref id="B50-ijms-26-06514"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fava</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Gatti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Belaise</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Offidani</surname><given-names>E.</given-names></name></person-group><article-title>Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review</article-title><source>Psychother. Psychosom.</source><year>2015</year><volume>84</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1159/000370338</pub-id><pub-id pub-id-type="pmid">25721705</pub-id></element-citation></ref><ref id="B51-ijms-26-06514"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuller-Thomson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sulman</surname><given-names>J.</given-names></name></person-group><article-title>Depression and inflammatory bowel disease: Findings from two nationally representative Canadian surveys</article-title><source>Inflamm. Bowel Dis.</source><year>2006</year><volume>12</volume><fpage>697</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1097/00054725-200608000-00005</pub-id><pub-id pub-id-type="pmid">16917224</pub-id></element-citation></ref><ref id="B52-ijms-26-06514"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haapam&#228;ki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roine</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Blom</surname><given-names>M.</given-names></name><name name-style="western"><surname>Turunen</surname><given-names>U.</given-names></name><name name-style="western"><surname>M&#228;ntyl&#228;</surname><given-names>J.</given-names></name><name name-style="western"><surname>F&#228;rkkil&#228;</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Arkkila</surname><given-names>P.E.T.</given-names></name></person-group><article-title>Medication use among inflammatory bowel disease patients: Excessive consumption of antidepressants and analgesics</article-title><source>Scand. J. Gastroenterol.</source><year>2013</year><volume>48</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.3109/00365521.2012.743584</pub-id><pub-id pub-id-type="pmid">23163864</pub-id></element-citation></ref><ref id="B53-ijms-26-06514"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikocka-Walus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prady</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Pollok</surname><given-names>J.</given-names></name><name name-style="western"><surname>Esterman</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>J.M.</given-names></name></person-group><article-title>Adjuvant therapy with antidepressants for the management of inflammatory bowel disease</article-title><source>Cochrane Database Syst. Rev.</source><year>2019</year><volume>4</volume><fpage>CD012680</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD012680.pub2</pub-id><pub-id pub-id-type="pmid">30977111</pub-id><pub-id pub-id-type="pmcid">PMC6459769</pub-id></element-citation></ref><ref id="B54-ijms-26-06514"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikocka-Walus</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Turnbull</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Moulding</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Holtmann</surname><given-names>G.J.</given-names></name></person-group><article-title>Antidepressants and inflammatory bowel disease: A systematic review</article-title><source>Clin. Pract. Epidemiol. Ment. Health</source><year>2006</year><volume>2</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/1745-0179-2-24</pub-id><pub-id pub-id-type="pmid">16984660</pub-id><pub-id pub-id-type="pmcid">PMC1599716</pub-id></element-citation></ref><ref id="B55-ijms-26-06514"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macer</surname><given-names>B.J.D.</given-names></name><name name-style="western"><surname>Prady</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Mikocka-Walus</surname><given-names>A.</given-names></name></person-group><article-title>Antidepressants in Inflammatory Bowel Disease: A Systematic Review</article-title><source>Inflamm. Bowel Dis.</source><year>2017</year><volume>23</volume><fpage>534</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000001059</pub-id><pub-id pub-id-type="pmid">28267046</pub-id></element-citation></ref><ref id="B56-ijms-26-06514"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frolkis</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Vallerand</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Shaheen</surname><given-names>A.-A.</given-names></name><name name-style="western"><surname>Lowerison</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Swain</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Barnabe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Patten</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>G.G.</given-names></name></person-group><article-title>Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression</article-title><source>Gut</source><year>2019</year><volume>68</volume><fpage>1606</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-317182</pub-id><pub-id pub-id-type="pmid">30337374</pub-id></element-citation></ref><ref id="B57-ijms-26-06514"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghia</surname><given-names>J.-E.</given-names></name><name name-style="western"><surname>Blennerhassett</surname><given-names>P.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>S.M.</given-names></name></person-group><article-title>Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression</article-title><source>J. Clin. Investig.</source><year>2008</year><volume>118</volume><fpage>2209</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1172/JCI32849</pub-id><pub-id pub-id-type="pmid">18451995</pub-id><pub-id pub-id-type="pmcid">PMC2350428</pub-id></element-citation></ref><ref id="B58-ijms-26-06514"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blennerhassett</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Verdu</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.I.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>S.M.</given-names></name></person-group><article-title>Reactivation of Inflammatory Bowel Disease in a Mouse Model of Depression</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>2280</fpage><lpage>2288.e4</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.02.069</pub-id><pub-id pub-id-type="pmid">19272381</pub-id></element-citation></ref><ref id="B59-ijms-26-06514"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wi&#281;d&#322;ocha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marcinowicz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Krupa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Janoska-Ja&#378;dzik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janus</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#281;bowska</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mosio&#322;ek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Waszkiewicz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Szulc</surname><given-names>A.</given-names></name></person-group><article-title>Effect of antidepressant treatment on peripheral inflammation markers&#8212;A meta-analysis</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2018</year><volume>80</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.04.026</pub-id><pub-id pub-id-type="pmid">28445690</pub-id></element-citation></ref><ref id="B60-ijms-26-06514"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rocchi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Escelsior</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fornaro</surname><given-names>M.</given-names></name></person-group><article-title>Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance</article-title><source>Curr. Neuropharmacol.</source><year>2012</year><volume>10</volume><fpage>97</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.2174/157015912800604542</pub-id><pub-id pub-id-type="pmid">23204981</pub-id><pub-id pub-id-type="pmcid">PMC3386509</pub-id></element-citation></ref><ref id="B61-ijms-26-06514"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varghese</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Verd&#250;</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Bercik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.I.</given-names></name><name name-style="western"><surname>Blennerhassett</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Szechtman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>S.M.</given-names></name></person-group><article-title>Antidepressants attenuate increased susceptibility to colitis in a murine model of depression</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1743</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2006.02.007</pub-id><pub-id pub-id-type="pmid">16697738</pub-id></element-citation></ref><ref id="B62-ijms-26-06514"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guemei</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>El Din</surname><given-names>N.M.N.</given-names></name><name name-style="western"><surname>Baraka</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>El Said Darwish</surname><given-names>I.</given-names></name></person-group><article-title>Do desipramine [10,11-dihydro-5-[3-(methylamino) propyl]-5H-dibenz[b,f]azepine monohydrochloride] and fluoxetine [N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan-1-amine] ameliorate the extent of colonic damage induced by acetic acid in rats?</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2008</year><volume>327</volume><fpage>846</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1124/jpet.108.141259</pub-id><pub-id pub-id-type="pmid">18791062</pub-id></element-citation></ref><ref id="B63-ijms-26-06514"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Min</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>Antidepressant fluoxetine alleviates colitis by reshaping intestinal microenvironment</article-title><source>Cell Commun. Signal.</source><year>2024</year><volume>22</volume><fpage>176</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-01538-5</pub-id><pub-id pub-id-type="pmid">38475799</pub-id><pub-id pub-id-type="pmcid">PMC10935910</pub-id></element-citation></ref><ref id="B64-ijms-26-06514"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Green</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Gouaux</surname><given-names>E.</given-names></name></person-group><article-title>X-ray structures and mechanism of the human serotonin transporter</article-title><source>Nature</source><year>2016</year><volume>532</volume><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nature17629</pub-id><pub-id pub-id-type="pmid">27049939</pub-id><pub-id pub-id-type="pmcid">PMC4898786</pub-id></element-citation></ref><ref id="B65-ijms-26-06514"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Mburu</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>S.N.</given-names></name></person-group><article-title>High-throughput screening for TLR3-IFN regulatory factor 3 signaling pathway modulators identifies several antipsychotic drugs as TLR inhibitors</article-title><source>J. Immunol.</source><year>2010</year><volume>184</volume><fpage>5768</fpage><lpage>5776</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903559</pub-id><pub-id pub-id-type="pmid">20382888</pub-id><pub-id pub-id-type="pmcid">PMC2874113</pub-id></element-citation></ref><ref id="B66-ijms-26-06514"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Branco-de-Almeida</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Kajiya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.J.B.</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rosalen</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>G.C.N.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Taubman</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name></person-group><article-title>Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2011</year><volume>62</volume><fpage>283</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2011.00816.x</pub-id><pub-id pub-id-type="pmid">21569123</pub-id><pub-id pub-id-type="pmcid">PMC3147168</pub-id></element-citation></ref><ref id="B67-ijms-26-06514"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vollmar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nessler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kalluri</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>H.-P.</given-names></name><name name-style="western"><surname>Hemmer</surname><given-names>B.</given-names></name></person-group><article-title>The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2009</year><volume>12</volume><fpage>525</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1017/S1461145708009425</pub-id><pub-id pub-id-type="pmid">18922202</pub-id></element-citation></ref><ref id="B68-ijms-26-06514"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rocchi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Escelsior</surname><given-names>A.</given-names></name><name name-style="western"><surname>Contini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Colicchio</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Berardis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Amore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fornaro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fornaro</surname><given-names>M.</given-names></name></person-group><article-title>NGF serum levels variations in major depressed patients receiving duloxetine</article-title><source>Psychoneuroendocrinology</source><year>2013</year><volume>38</volume><fpage>1824</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.02.009</pub-id><pub-id pub-id-type="pmid">23507186</pub-id></element-citation></ref><ref id="B69-ijms-26-06514"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fornaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Battaglia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Colicchio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perugi</surname><given-names>G.</given-names></name></person-group><article-title>Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: A preliminary observation</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2011</year><volume>7</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.2147/NDT.S16382</pub-id><pub-id pub-id-type="pmid">21430794</pub-id><pub-id pub-id-type="pmcid">PMC3056173</pub-id></element-citation></ref><ref id="B70-ijms-26-06514"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ba&#351;terzi</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Yazici</surname><given-names>K.</given-names></name><name name-style="western"><surname>Buturak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cimen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yazici</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eskandari</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tot Acar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ta&#351;delen</surname><given-names>B.</given-names></name></person-group><article-title>Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: A flow cytometric analysis</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2010</year><volume>34</volume><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2009.09.025</pub-id><pub-id pub-id-type="pmid">19804808</pub-id></element-citation></ref><ref id="B71-ijms-26-06514"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saraykar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>H.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Dantzer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Selvaraj</surname><given-names>S.</given-names></name></person-group><article-title>Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies</article-title><source>Neurosci. Biobehav. Rev.</source><year>2018</year><volume>92</volume><fpage>477</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.05.031</pub-id><pub-id pub-id-type="pmid">29940237</pub-id><pub-id pub-id-type="pmcid">PMC6686193</pub-id></element-citation></ref><ref id="B72-ijms-26-06514"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Raison</surname><given-names>C.L.</given-names></name></person-group><article-title>The role of inflammation in depression: From evolutionary imperative to modern treatment target</article-title><source>Nat. Rev. Immunol.</source><year>2016</year><volume>16</volume><fpage>22</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/nri.2015.5</pub-id><pub-id pub-id-type="pmid">26711676</pub-id><pub-id pub-id-type="pmcid">PMC5542678</pub-id></element-citation></ref><ref id="B73-ijms-26-06514"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sforzini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nettis</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mondelli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pariante</surname><given-names>C.M.</given-names></name></person-group><article-title>Inflammation in cancer and depression: A starring role for the kynurenine pathway</article-title><source>Psychopharmacology</source><year>2019</year><volume>236</volume><fpage>2997</fpage><lpage>3011</lpage><pub-id pub-id-type="doi">10.1007/s00213-019-05200-8</pub-id><pub-id pub-id-type="pmid">30806743</pub-id><pub-id pub-id-type="pmcid">PMC6820591</pub-id></element-citation></ref><ref id="B74-ijms-26-06514"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umehara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Numata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Hatakeyama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tomioka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohmori</surname><given-names>T.</given-names></name></person-group><article-title>Altered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>4855</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-05121-6</pub-id><pub-id pub-id-type="pmid">28687801</pub-id><pub-id pub-id-type="pmcid">PMC5501805</pub-id></element-citation></ref><ref id="B75-ijms-26-06514"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name></person-group><article-title>Interactions Between Antidepressants and Intestinal Microbiota</article-title><source>Neurotherapeutics</source><year>2023</year><volume>20</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1007/s13311-023-01362-8</pub-id><pub-id pub-id-type="pmid">36881351</pub-id><pub-id pub-id-type="pmcid">PMC10121977</pub-id></element-citation></ref><ref id="B76-ijms-26-06514"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luki&#263;</surname><given-names>I.</given-names></name><name name-style="western"><surname>Getselter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ziv</surname><given-names>O.</given-names></name><name name-style="western"><surname>Oron</surname><given-names>O.</given-names></name><name name-style="western"><surname>Reuveni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koren</surname><given-names>O.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>E.</given-names></name></person-group><article-title>Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior</article-title><source>Transl. Psychiatry</source><year>2019</year><volume>9</volume><fpage>133</fpage><pub-id pub-id-type="doi">10.1038/s41398-019-0466-x</pub-id><pub-id pub-id-type="pmid">30967529</pub-id><pub-id pub-id-type="pmcid">PMC6456569</pub-id></element-citation></ref><ref id="B77-ijms-26-06514"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name></person-group><article-title>Antidepressants fluoxetine and amitriptyline induce alterations in intestinal microbiota and gut microbiome function in rats exposed to chronic unpredictable mild stress</article-title><source>Transl. Psychiatry</source><year>2021</year><volume>11</volume><fpage>131</fpage><pub-id pub-id-type="doi">10.1038/s41398-021-01254-5</pub-id><pub-id pub-id-type="pmid">33602895</pub-id><pub-id pub-id-type="pmcid">PMC7892574</pub-id></element-citation></ref><ref id="B78-ijms-26-06514"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Getachew</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aubee</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Schottenfeld</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Csoka</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Tizabi</surname><given-names>Y.</given-names></name></person-group><article-title>Ketamine interactions with gut-microbiota in rats: Relevance to its antidepressant and anti-inflammatory properties</article-title><source>BMC Microbiol.</source><year>2018</year><volume>18</volume><elocation-id>222</elocation-id><pub-id pub-id-type="doi">10.1186/s12866-018-1373-7</pub-id><pub-id pub-id-type="pmid">30579332</pub-id><pub-id pub-id-type="pmcid">PMC6303954</pub-id></element-citation></ref><ref id="B79-ijms-26-06514"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkinshaw</surname><given-names>H.</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>P.</given-names></name><name name-style="western"><surname>Eccleston</surname><given-names>C.</given-names></name><name name-style="western"><surname>Serfaty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>G.</given-names></name><name name-style="western"><surname>White</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Phillippo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pincus</surname><given-names>T.</given-names></name></person-group><article-title>Antidepressants for pain management in adults with chronic pain: A network meta-analysis</article-title><source>Cochrane Database Syst. Rev.</source><year>2023</year><volume>5</volume><fpage>CD014682</fpage><pub-id pub-id-type="doi">10.3310/MKRT2948</pub-id><pub-id pub-id-type="pmid">37160297</pub-id><pub-id pub-id-type="pmcid">PMC10169288</pub-id></element-citation></ref><ref id="B80-ijms-26-06514"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.-Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.-R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.-P.</given-names></name></person-group><article-title>Modulation of pain transmission by G-protein-coupled receptors</article-title><source>Pharmacol. Ther.</source><year>2008</year><volume>117</volume><fpage>141</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2007.09.003</pub-id><pub-id pub-id-type="pmid">17959251</pub-id><pub-id pub-id-type="pmcid">PMC2965406</pub-id></element-citation></ref><ref id="B81-ijms-26-06514"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#246;hler-Forsberg</surname><given-names>O.</given-names></name><name name-style="western"><surname>Stiglbauer</surname><given-names>V.</given-names></name><name name-style="western"><surname>Brasanac</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Wagener</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zimbalski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jefsen</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seals</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Gamradt</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of Antidepressants in Patients With Comorbid Depression and Medical Diseases: An Umbrella Systematic Review and Meta-Analysis</article-title><source>JAMA Psychiatry</source><year>2023</year><volume>80</volume><fpage>1196</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2023.2983</pub-id><pub-id pub-id-type="pmid">37672261</pub-id><pub-id pub-id-type="pmcid">PMC10483387</pub-id></element-citation></ref><ref id="B82-ijms-26-06514"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lippi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paci</surname><given-names>R.</given-names></name><name name-style="western"><surname>Del Fabro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Delvecchio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brambilla</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Ronchi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fanelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Serretti</surname><given-names>A.</given-names></name></person-group><article-title>Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2021</year><volume>109</volume><elocation-id>110266</elocation-id><pub-id pub-id-type="doi">10.1016/j.pnpbp.2021.110266</pub-id><pub-id pub-id-type="pmid">33549697</pub-id></element-citation></ref><ref id="B83-ijms-26-06514"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barros</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Farias</surname><given-names>A.Q.</given-names></name><name name-style="western"><surname>Rezaie</surname><given-names>A.</given-names></name></person-group><article-title>Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment</article-title><source>World. J. Gastroenterol.</source><year>2019</year><volume>25</volume><fpage>4414</fpage><lpage>4426</lpage><pub-id pub-id-type="doi">10.3748/wjg.v25.i31.4414</pub-id><pub-id pub-id-type="pmid">31496621</pub-id><pub-id pub-id-type="pmcid">PMC6710178</pub-id></element-citation></ref><ref id="B84-ijms-26-06514"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tack</surname><given-names>J.</given-names></name><name name-style="western"><surname>Broekaert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Corsetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fischler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>J.</given-names></name></person-group><article-title>Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man</article-title><source>Aliment. Pharmacol. Ther.</source><year>2006</year><volume>23</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02724.x</pub-id><pub-id pub-id-type="pmid">16393306</pub-id></element-citation></ref><ref id="B85-ijms-26-06514"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenna</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>de los Angeles</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Koran</surname><given-names>L.M.</given-names></name></person-group><article-title>Psychiatric complications of treatment with corticosteroids: Review with case report</article-title><source>Psychiatry Clin. Neurosci.</source><year>2011</year><volume>65</volume><fpage>549</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1819.2011.02260.x</pub-id><pub-id pub-id-type="pmid">22003987</pub-id></element-citation></ref><ref id="B86-ijms-26-06514"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Minozzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kopylov</surname><given-names>U.</given-names></name><name name-style="western"><surname>Verstockt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chaparro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Buskens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Warusavitarne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allocca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Atreya</surname><given-names>R.</given-names></name><etal/></person-group><article-title>ECCO Guidelines on Therapeutics in Crohn&#8217;s Disease: Medical Treatment</article-title><source>J. Crohn&#8217;s Colitis</source><year>2024</year><volume>18</volume><fpage>1531</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjae091</pub-id><pub-id pub-id-type="pmid">38877997</pub-id></element-citation></ref><ref id="B87-ijms-26-06514"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Suppes</surname><given-names>T.</given-names></name></person-group><article-title>Mood symptoms during corticosteroid therapy: A review</article-title><source>Harv. Rev. Psychiatry</source><year>1998</year><volume>5</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.3109/10673229809000307</pub-id><pub-id pub-id-type="pmid">9493946</pub-id></element-citation></ref><ref id="B88-ijms-26-06514"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ford</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Vanner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kashyap</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>Y.</given-names></name></person-group><article-title>Chronic Visceral Pain: New Peripheral Mechanistic Insights and Resulting Treatments</article-title><source>Gastroenterology</source><year>2024</year><volume>166</volume><fpage>976</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2024.01.045</pub-id><pub-id pub-id-type="pmid">38325759</pub-id><pub-id pub-id-type="pmcid">PMC11102851</pub-id></element-citation></ref><ref id="B89-ijms-26-06514"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sternini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Patierno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Selmer</surname><given-names>I.-S.</given-names></name><name name-style="western"><surname>Kirchgessner</surname><given-names>A.</given-names></name></person-group><article-title>The opioid system in the gastrointestinal tract</article-title><source>Neurogastroenterol. Motil.</source><year>2004</year><volume>16</volume><fpage>3</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1111/j.1743-3150.2004.00553.x</pub-id><pub-id pub-id-type="pmid">15357847</pub-id></element-citation></ref><ref id="B90-ijms-26-06514"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramanathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Panksepp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.</given-names></name></person-group><article-title>Is Fibromyalgia An Endocrine/Endorphin Deficit Disorder? Is Low Dose Naltrexone a New Treatment Option?</article-title><source>Psychosomatics</source><year>2012</year><volume>53</volume><fpage>591</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/j.psym.2011.11.006</pub-id><pub-id pub-id-type="pmid">22480625</pub-id></element-citation></ref><ref id="B91-ijms-26-06514"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>L.R.</given-names></name></person-group><article-title>Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4</article-title><source>Br. J. Pharmacol.</source><year>2016</year><volume>173</volume><fpage>856</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1111/bph.13394</pub-id><pub-id pub-id-type="pmid">26603732</pub-id><pub-id pub-id-type="pmcid">PMC4761092</pub-id></element-citation></ref><ref id="B92-ijms-26-06514"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watkins</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>M.R.</given-names></name></person-group><article-title>In vivo veritas: (+)-Naltrexone&#8217;s actions define translational importance</article-title><source>Trends Pharmacol. Sci.</source><year>2014</year><volume>35</volume><fpage>432</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.07.002</pub-id><pub-id pub-id-type="pmid">25109571</pub-id></element-citation></ref><ref id="B93-ijms-26-06514"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deuring</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Fuhler</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Konstantinov</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Peppelenbosch</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Kuipers</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>De Haar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van Der Woude</surname><given-names>C.J.</given-names></name></person-group><article-title>Genomic ATG16L1 risk allele-restricted Paneth cell ER stress in quiescent Crohn&#8217;s disease</article-title><source>Gut</source><year>2014</year><volume>63</volume><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2012-303527</pub-id><pub-id pub-id-type="pmid">23964099</pub-id></element-citation></ref><ref id="B94-ijms-26-06514"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moslehi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nabavizadeh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zekri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Amiri</surname><given-names>F.</given-names></name></person-group><article-title>Naltrexone changes the expression of lipid metabolism&#8212;Related proteins in the endoplasmic reticulum stress induced hepatic steatosis in mice</article-title><source>Clin. Exp. Pharma. Physio.</source><year>2017</year><volume>44</volume><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1111/1440-1681.12695</pub-id><pub-id pub-id-type="pmid">27813192</pub-id></element-citation></ref><ref id="B95-ijms-26-06514"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moslehi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nabavizadeh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dehpou</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Tavanga</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hassanzadeh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zekri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nahrevanian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sohanaki</surname><given-names>H.</given-names></name></person-group><article-title>Naltrexone attenuates endoplasmic reticulum stress induced hepatic injury in mice</article-title><source>Acta Physiol. Hung.</source><year>2014</year><volume>101</volume><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1556/APhysiol.101.2014.3.9</pub-id><pub-id pub-id-type="pmid">25183508</pub-id></element-citation></ref><ref id="B96-ijms-26-06514"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tawfik</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Osman</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Tolba</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Khattab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdel-Salam</surname><given-names>L.O.</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>M.M.</given-names></name></person-group><article-title>Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn&#8217;s disease in rats</article-title><source>Neuropeptides</source><year>2016</year><volume>59</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.npep.2016.06.003</pub-id><pub-id pub-id-type="pmid">27392602</pub-id></element-citation></ref><ref id="B97-ijms-26-06514"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alcaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>R.</given-names></name><name name-style="western"><surname>Panksepp</surname><given-names>J.</given-names></name></person-group><article-title>Behavioral functions of the mesolimbic dopaminergic system: An affective neuroethological perspective</article-title><source>Brain Res. Rev.</source><year>2007</year><volume>56</volume><fpage>283</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.brainresrev.2007.07.014</pub-id><pub-id pub-id-type="pmid">17905440</pub-id><pub-id pub-id-type="pmcid">PMC2238694</pub-id></element-citation></ref><ref id="B98-ijms-26-06514"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>N.</given-names></name><name name-style="western"><surname>Panksepp</surname><given-names>J.</given-names></name></person-group><article-title>Low-dose naltrexone for disease prevention and quality of life</article-title><source>Med. Hypotheses</source><year>2009</year><volume>72</volume><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2008.06.048</pub-id><pub-id pub-id-type="pmid">19041189</pub-id></element-citation></ref><ref id="B99-ijms-26-06514"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghia</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Blennerhassett</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kumar&#8211;Ondiveeran</surname><given-names>H.</given-names></name><name name-style="western"><surname>Verdu</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>S.M.</given-names></name></person-group><article-title>The Vagus Nerve: A Tonic Inhibitory Influence Associated With Inflammatory Bowel Disease in a Murine Model</article-title><source>Gastroenterology</source><year>2006</year><volume>131</volume><fpage>1122</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2006.08.016</pub-id><pub-id pub-id-type="pmid">17030182</pub-id></element-citation></ref><ref id="B100-ijms-26-06514"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernik</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Ochani</surname><given-names>M.</given-names></name><name name-style="western"><surname>DiRaimo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ulloa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sudan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Czura</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Tracey</surname><given-names>K.J.</given-names></name></person-group><article-title>Pharmacological Stimulation of the Cholinergic Antiinflammatory Pathway</article-title><source>J. Exp. Med.</source><year>2002</year><volume>195</volume><fpage>781</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1084/jem.20011714</pub-id><pub-id pub-id-type="pmid">11901203</pub-id><pub-id pub-id-type="pmcid">PMC2193742</pub-id></element-citation></ref><ref id="B101-ijms-26-06514"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pullan</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ganesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Newcombe</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feyerabend</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Transdermal Nicotine for Active Ulcerative Colitis</article-title><source>N. Engl. J. Med.</source><year>1994</year><volume>330</volume><fpage>811</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1056/NEJM199403243301202</pub-id><pub-id pub-id-type="pmid">8114833</pub-id></element-citation></ref><ref id="B102-ijms-26-06514"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motavallian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zamani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rezaeyan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Karimian</surname><given-names>P.</given-names></name><name name-style="western"><surname>Evazalipour</surname><given-names>M.</given-names></name></person-group><article-title>Anti-inflammatory effect of pregabalin on acetic acid-induced colitis in the rats</article-title><source>Res. Pharm. Sci.</source><year>2022</year><volume>17</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.4103/1735-5362.329924</pub-id><pub-id pub-id-type="pmid">34909042</pub-id><pub-id pub-id-type="pmcid">PMC8621841</pub-id></element-citation></ref><ref id="B103-ijms-26-06514"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name></person-group><article-title>Lithium carbonate alleviates colon inflammation through modulating gut microbiota and Treg cells in a GPR43-dependent manner</article-title><source>Pharmacol. Res.</source><year>2022</year><volume>175</volume><fpage>105992</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105992</pub-id><pub-id pub-id-type="pmid">34801681</pub-id></element-citation></ref><ref id="B104-ijms-26-06514"><label>104.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Allergan USA, Inc</collab></person-group><article-title>Highlights of Prescribing Information Celexa&#174; (Citalopram). Ref. ID 4933291. Published Online February 2022</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B105-ijms-26-06514"><label>105.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Abbvie Inc</collab></person-group><article-title>Highlights of Prescribing Information Lexapro&#174; (Escitalopram). Reference ID: 5367836. Published Online April 2024</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B106-ijms-26-06514"><label>106.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Jazz Pharmaceuticals, Inc</collab></person-group><article-title>Highlights of Prescribing Information Luvox&#174; (Fluvoxamine Maleate). Published Online 2008</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022235lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022235lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B107-ijms-26-06514"><label>107.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Apotex Inc</collab></person-group><article-title>Highlights of Prescribing Information Paxil (Paroxetine). Reference ID: 5274678. Published Online August 2023</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020031s082lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020031s082lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B108-ijms-26-06514"><label>108.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Viatris Specialty LLC</collab></person-group><article-title>Highlights of Prescribing Information ZOLOFT (Sertraline Hydrochloride). Reference ID: 5229497. Published Online August 2023</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019839s108,20990s062lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019839s108,20990s062lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B109-ijms-26-06514"><label>109.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Lilly USA, LLC</collab></person-group><article-title>Highlights of Prescribing Information Cymbalta&#174; (Duloxetine Delayed-Release Capsules). Reference ID: 5229383. Published Online August 2023</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B110-ijms-26-06514"><label>110.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Viatris Specialty LLC</collab></person-group><article-title>Highlights of Prescribing Information Effexor XR&#174; (Venlafaxine Extended-Release). Reference ID: 5229419. Published Online August 2023</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B111-ijms-26-06514"><label>111.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>GlaxoSmithKline</collab></person-group><article-title>Highlights of Prescribing Information Wellbutrin (Bupropion Hydrochloride). Reference ID: 5376823. Published Online April 2024</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018644s061lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018644s061lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B112-ijms-26-06514"><label>112.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Merck &amp; Co Inc</collab></person-group><article-title>Highlights of Prescribing Information Remeron&#174; (Mirtazapine). Reference ID: 4878026. Published Online November 2021</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020415s038,021208s028lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020415s038,021208s028lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B113-ijms-26-06514"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norman</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Olver</surname><given-names>J.S.</given-names></name></person-group><article-title>Agomelatine for depression: Expanding the horizons?</article-title><source>Expert Opin Pharmacother.</source><year>2019</year><volume>20</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1080/14656566.2019.1574747</pub-id><pub-id pub-id-type="pmid">30759026</pub-id></element-citation></ref><ref id="B114-ijms-26-06514"><label>114.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Moraczewski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Awosika</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Aedma</surname><given-names>K.K.</given-names></name></person-group><article-title>Tricyclic Antidepressants</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK557791/" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/books/NBK557791/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-24">(accessed on 24 July 2024)</date-in-citation><pub-id pub-id-type="pmid">32491723</pub-id></element-citation></ref><ref id="B115-ijms-26-06514"><label>115.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sabri</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Saber-Ayad</surname><given-names>M.M.</given-names></name></person-group><article-title>MAO Inhibitors</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK557395/" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/books/NBK557395/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-24">(accessed on 24 July 2024)</date-in-citation><pub-id pub-id-type="pmid">32491327</pub-id></element-citation></ref><ref id="B116-ijms-26-06514"><label>116.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Janssen Ortho LLC</collab></person-group><article-title>Highlights of Prescribing Information Topamax&#174; (Topiramate). Reference ID: 5167873. Published Online May 2023</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020505s065,020844s056lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020505s065,020844s056lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B117-ijms-26-06514"><label>117.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>West-Ward Pharmaceuticals</collab></person-group><article-title>Highlights of Prescribing Information Lithium and Lithium Carbonate. Reference ID: 5060222. Published Online October 2022</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/017812s036,018421s035,018558s030lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/017812s036,018421s035,018558s030lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B118-ijms-26-06514"><label>118.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Duramed Pharmaceuticals, Inc</collab></person-group><article-title>Highlights of Prescribing Information Revia&#174; (Naltrexone Hydrochloride). Reference ID: 3383348. Published Online October 2013</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B119-ijms-26-06514"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Morford</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Levander</surname><given-names>X.A.</given-names></name></person-group><article-title>Benzodiazepines and Related Sedatives</article-title><source>Med. Clin. N. Am.</source><year>2022</year><volume>106</volume><fpage>113</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.mcna.2021.08.012</pub-id><pub-id pub-id-type="pmid">34823725</pub-id></element-citation></ref><ref id="B120-ijms-26-06514"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siriwardena</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Latham</surname><given-names>M.</given-names></name></person-group><article-title>GPs&#8217; attitudes to benzodiazepine and &#8220;Z-drug&#8221; prescribing: A barrier to implementation of evidence and guidance on hypnotics</article-title><source>Br. J. Gen. Pract.</source><year>2006</year><volume>56</volume><fpage>964</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">17132386</pub-id><pub-id pub-id-type="pmcid">PMC1934058</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-26-06514-f001" orientation="portrait"><label>Figure 1</label><caption><p>PRISMA flow diagram describing the paper selection process.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-06514-g001.jpg"/></fig><fig position="float" id="ijms-26-06514-f002" orientation="portrait"><label>Figure 2</label><caption><p>Graphical summary of the studies included in the systematic review. This table summarizes the key studies included in this review, highlighting the effectiveness of certain psychotropic drugs on both gastrointestinal and psychiatric outcomes. The studies are organized by drug class&#8212;Antidepressants (Daghdhaghzadeh et al., 2015 [<xref rid="B30-ijms-26-06514" ref-type="bibr">30</xref>], Yanarta&#351; et al., 2016 [<xref rid="B27-ijms-26-06514" ref-type="bibr">27</xref>], Liang et al., 2022 [<xref rid="B31-ijms-26-06514" ref-type="bibr">31</xref>], Chojnacki et al., 2011 [<xref rid="B33-ijms-26-06514" ref-type="bibr">33</xref>], Iskandar et al., 2014 [<xref rid="B32-ijms-26-06514" ref-type="bibr">32</xref>], Goodhand et al., 2012 [<xref rid="B28-ijms-26-06514" ref-type="bibr">28</xref>], Mikocka-Walus et al., 2017 [<xref rid="B29-ijms-26-06514" ref-type="bibr">29</xref>], Kane et al., 2003 [<xref rid="B34-ijms-26-06514" ref-type="bibr">34</xref>], Kast and Altschuler, 2001 [<xref rid="B35-ijms-26-06514" ref-type="bibr">35</xref>], Kast et al., 1998 [<xref rid="B36-ijms-26-06514" ref-type="bibr">36</xref>], Hall et al., 2018 [<xref rid="B25-ijms-26-06514" ref-type="bibr">25</xref>]), Antiepileptics and Mood Stabilizers (Crockett et al., 2014 [<xref rid="B38-ijms-26-06514" ref-type="bibr">38</xref>], D&#8217;Onofrio et al., 2024 [<xref rid="B39-ijms-26-06514" ref-type="bibr">39</xref>], Zissok, 1972 [<xref rid="B42-ijms-26-06514" ref-type="bibr">42</xref>]), and Others (Furlan et al., 2006 [<xref rid="B48-ijms-26-06514" ref-type="bibr">48</xref>], Lechin et al., 1985 [<xref rid="B47-ijms-26-06514" ref-type="bibr">47</xref>], Lie et al., 2018 [<xref rid="B43-ijms-26-06514" ref-type="bibr">43</xref>], Paulides et al., 2022 [<xref rid="B49-ijms-26-06514" ref-type="bibr">49</xref>], Smith et al., 2011 [<xref rid="B44-ijms-26-06514" ref-type="bibr">44</xref>], Smith et al., 2007 [<xref rid="B45-ijms-26-06514" ref-type="bibr">45</xref>], Smith et al., 2013 [<xref rid="B46-ijms-26-06514" ref-type="bibr">46</xref>]). The study by Kristensen et al., 2019 [<xref rid="B26-ijms-26-06514" ref-type="bibr">26</xref>] was not included because there are no psychiatric/gastroenterological outcomes available for specific psychotropic drugs, but only for classes of drugs (antidepressants). Note: CR (Case-report); CS (Case-series); NASSa (Noradrenaline and specific serotonergic antidepressants); SNRI (Serotonin and norepinephrine reuptake inhibitors); SSRI (Selective serotonin reuptake inhibitors); TCA (Tricyclic antidepressants).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-06514-g002.jpg"/></fig><fig position="float" id="ijms-26-06514-f003" orientation="portrait"><label>Figure 3</label><caption><p>Molecular and immunological mechanisms underlying the anti-inflammatory effects of selected psychiatric medications in inflammatory bowel disease. Selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), venlafaxine, and duloxetine contribute to inflammation modulation through the promotion of M2 macrophage polarization, increased production of anti-inflammatory cytokines (e.g., IL-10, TGF-&#946;), reduction in Paneth cell-mediated epithelial inflammation, and modulation of gut microbiota composition. These drugs also induce a Th1-to-Th2 cytokine shift, reducing pro-inflammatory mediators such as TNF-&#945;, IL-1&#946;, and IFN-&#947;. Naltrexone inhibits lipopolysaccharide (LPS)-induced TLR4 signaling, reducing ER stress in Paneth cells and the expression of pro-inflammatory interferon genes. Clonidine activates the cholinergic anti-inflammatory pathway (CAIP), resulting in decreased TNF-&#945; levels via autonomic nervous system modulation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-06514-g003.jpg"/></fig><table-wrap position="float" id="ijms-26-06514-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-26-06514-t001_Table 1</object-id><label>Table 1</label><caption><p>Included studies on antidepressants for gastrointestinal outcomes in IBD patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Measurement and Assessment</th><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Results</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Author (Year), Ref.</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Population</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychiatric Condition</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychiatric Condition</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Follow-Up</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daghaghzadeh, et al. (2015) [<xref rid="B30-ijms-26-06514" ref-type="bibr">30</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duloxetina</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35 adult IBD patients (no flare up in the previous 6 months) <break/>
CD = 13<break/>
UC = 22</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Placebo-controlled RCT:<break/>
Study group (n = 17) treated with duloxetine 30&#8211;60 mg daily for 12 weeks.<break/>
Control group (n = 18) treated with placebo. Both groups also received a stable dose of mesalazine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The severity of symptoms was assessed with LCAI</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anxiety and depression were assessed with HADS. The QOL was assessed with WHOQOL-BREF.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severity of symptoms was significantly decreased in the duloxetine group compared to the placebo group.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Depression and anxiety were significantly decreased in the duloxetin group compared to the placebo group. Physical, psychological, and social QoL were significantly increased after treatment with duloxetine.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 weeks</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yanartas et al. (2016) [<xref rid="B27-ijms-26-06514" ref-type="bibr">27</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sertraline 21.0%, escitalopram 15.8%, bupropion 12.3%, mirtazapine 12.3%, paroxetine 10.6%, venlafaxine 5.2%, duloxetine 3.5%, fluvoxamine 1.8%, antidepressant combination treatment</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67 patients with IBD and anxiety and/or a depression disorder<break/>
CD = 31<break/>
UC = 36</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort study:<break/>
Patients were divided into 2 groups:<break/>
Group A (47 patients who had completely adhered to the 6-month drug treatment Group B (20 patients who were nonadherent)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDAI and modified MMS were used for the assessment of disease activity in patients with CD or UC, respectively, along with CRP, complete blood count, and routine blood biochemistry</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anxiety and depression were assessed with HADS.<break/>
SF-36 and ASEX tests were used to assess QoL and sexual dysfunction</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemoglobin plus CDAI parameters were statistically improved at the final visit in group A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HAD-Anxiety (HAD-A), HAD-Depression (HAD-D), all domains of SF-36, ASEX were statistically improved at the final visit in group A.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 months</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iskandar et al. (2014) [<xref rid="B32-ijms-26-06514" ref-type="bibr">32</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81 patients with IBD in clinical remission/mild activity and IBS<break/>
UC = 23 <break/>
CD = 58</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study:<break/>
IBD patients in clinical remission/with mild inflammation but with persistent GI symptoms were treated with<break/>
TCA (10&#8211;150 mg).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Established Likert scales were used to score baseline symptom severity (0 = no symptoms, 3 = severe symptoms) and TCA response (0 = no improvement; 3 = complete satisfaction).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline severity scores (CD: 2.07 &#177; 0.03, UC: 2.03 &#177; 0.04, <italic toggle="yes">p</italic> = 0.67), <break/>
UC patients responded significantly better to TCA therapy, with a Likert response score of 1.86 &#177; 0.13 for UC and 1.26 &#177; 0.11 for CD (<italic toggle="yes">p</italic> = 0.003). <break/>
83% of UC patients had at least a moderate symptomatic improvement on TCA, compared with 50% of CD patients (<italic toggle="yes">p</italic> = 0.01). </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 years</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goodhand et al. (2012) [<xref rid="B28-ijms-26-06514" ref-type="bibr">28</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citalopram 20 mg (20&#8211;60 mg) and fluoxetine 20 mg (20&#8211;60 mg) were the most used. Others were SSRIs, TCA, NaSSa, and SNRIs.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58 IBD patients divided into 2 groups (n = 29 IBD patients on antidepressant, and n = 29 IBD control patients not on antidepressant). <break/>
Patients were treated also with corticosteroids, 5-ASA, immunosuppressive agents and anti-TNF-&#945;.<break/>
UC = 14<break/>
CD = 15<break/>
(in each group)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective case&#8211;control study:<break/>
Comparison of the course of IBD patients during the year before (year 1) and after (year 2) they were started on an antidepressant to that of controls matched for age, sex, disease type, medication at baseline, and relapse rate in year 1. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The outcome measures were the number of relapses, number of endoscopic procedures, number of hospital admissions and outpatient attendances, numbers of courses of steroids and relapse-related use of other IBD medications.<break/>
Disease activity was defined as the presence of diarrhea and rectal bleeding in UC, the presence of abdominal pain and/or diarrhea and/or a CRP &gt;10 mg/L in CD, a relapse was defined as the presence of these symptoms with a step-up in IBD medication. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients had fewer relapses and courses of steroids in the year after starting an antidepressant than in the year before (1 [0&#8211;4] (median [range]) vs. 0 [0&#8211;4], <italic toggle="yes">p</italic> = 0.002; 1 [0&#8211;3] vs. 0 [0&#8211;4], <italic toggle="yes">p</italic> &lt; 0.001, respectively); the controls showed no changes between years 1 and 2 in relapses or courses of steroids </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 years</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mikocka-Walus et al. (2017) [<xref rid="B29-ijms-26-06514" ref-type="bibr">29</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoxetina 20 mg daily</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 adult patients with clinically established diagnosis of CD, in clinical remission but who flared CD in the last 12 month.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pilot Randomized Placebo-Controlled Trial:<break/>
Study group: 14 patients treated with fluoxetine Placebo group: 12 patients.<break/>
Patients in both treatment arms remained on their current IBD medication. Participants provided blood and stool samples and complete questionnaires on four occasions [baseline, 3, 6 and 12 months]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The primary outcome measures were a significant group difference in the CD remission rate as measured on the CDAI [cut-off &lt; 150]. The secondary measure was difference on remission rates as measured by fecal calprotectin;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The primary outcome was the difference in means on the WHOQo.<break/>
Secondary measures were differences between HADS.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There was no statistically significant difference in the proportion of participants in remission at any time point,<break/>
using either the CDAI [F(3, 27.5) = 0.064, <italic toggle="yes">p</italic> = 0.978] or fecal calprotectin [F (3, 32.5) = 1.08, <italic toggle="yes">p</italic> = 0.371],</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There was no significant group difference in physical QoL, psychological QoL, social relationships QoL or environmental QoL over the 12 months. There was no significant group difference in anxiety or depression over the 12 months.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 months</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kane et al. (2003) [<xref rid="B34-ijms-26-06514" ref-type="bibr">34</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Buproprion (100 mg)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 CD patients </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case series: Bupropion (100 mg) was prescribed for depression or smoking cessation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outcome measurements: CDAI.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two patients were diagnosed with depression </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDAI decreased to 150 within 6 weeks without a change in other Crohn&#8217;s medications</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 weeks</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kast and Altschuler et al. (2001) [<xref rid="B35-ijms-26-06514" ref-type="bibr">35</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupropion</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44-year-old woman with CD, taking fluoxetine 40 mg every day for depression, and mesalamine 500 mg twice a day.<break/>
45-year-old-man with CD, taking azathioprine and fluoxetine to help with pain control (then switched to bupropion)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case series: Female: Bupropion 150 mg 3 times daily for depression and dysthymia. Fluoxetine was stopped and mesalamine was tapered off.<break/>
Male: Bupropion 150 mg 3 times daily for smoking cessation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outcome measurements: CDAI<break/>
Woman: <break/>
CDAI was 202.<break/>
Man: <break/>
CDAI was 275.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Woman had an episode of major depression, superimposed on a chronic mild depressed state (dysthymia). </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female: 19-month remission, no CD flares since starting bupropion. She stopped buproprion on her own but had a relapse and was forced to restart buproprion. CDAI = 0.<break/>
Male: CDAI = 45. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female: major depression remitted; dysthymia remained.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Woman: 19 months<break/>
Man: not reported</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kast et al. (1998) [<xref rid="B36-ijms-26-06514" ref-type="bibr">36</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phenelzine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33-year-old woman with CD.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report:<break/>
Phenelzine 15 mg three times daily for one month, then 30 mg 3 times daily for 2 years.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outcome measurements: clinical symptoms, such as diarrhea and abdominal pain.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">She had an anxiety-prominent major depressive episode.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Seven days after phenelzine intake, bowel movements dropped from 10 to 3 or 4 daily without cramping. One month later, after increasing phenelzine 30 mg three times daily, she had 1 well-formed bowel movement daily and no cramping. Azathioprine and prednisone were tapered off.<break/>
Two years after she switched to nortriptyline and after 6 weeks was admitted to the hospital with CD relapse. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Depression responded well.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 years</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liang et al. (2022) [<xref rid="B31-ijms-26-06514" ref-type="bibr">31</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venlafaxine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 patients with IBD were included<break/>
UC = 21<break/>
CD = 25 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, randomized, double-blind, and placebo-controlled clinical trial.<break/>
IBD patients with symptoms of anxiety or depression were randomly assigned to receive either venlafaxine 150 mg daily or equivalent placebo and followed for 6 months (25 received venlafaxine and 20 placebo).<break/>
IBDQ, Mayo score, CDAI, HADS and blood examination were completed before the enrollment, during, and after the follow-up. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The primary outcome measures were as follows: the IBDQ score and CDAI for CD and Mayo score for UC at the onset, 3 months, and 6 months, which were analyzed in the complete case population. The secondary outcome measures were the disease course, SES-CD, UCEIS, relapse rate, frequency of corticosteroids/biologics use, and laboratory parameters (WBC, ALB, CRP, ESR, TNF-&#945;, IL-10) between the venlafaxine and placebo groups</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychiatric outcome measures were the means on the Hospital Anxiety Depression Scale (HADS, measured on three occasions.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBDQ scores were significantly higher in the venlafaxine group compared with placebo group (3 months: comparison of effect size:0.59, <italic toggle="yes">p</italic> = 0.005; 6 months: comparison of effect size: 1.19, <italic toggle="yes">p</italic> &lt; 0.001. UC patients with venlafaxine had lower Mayo score than that in placebo group after the 6-month assessment (comparison of effect size: &#8722;1.47, <italic toggle="yes">p</italic> &lt; 0.001). Venlafaxine showed significant decrease in CDAI scores compared with placebo at 6 months (comparison of effect size: &#8722;0.87, <italic toggle="yes">p</italic> = 0.006). No significant differences were observed between the 2 groups in 3 months.<break/>
UCEIS (1.9 vs. 1.7, <italic toggle="yes">p</italic> = 0.249) and SES-CD (4.6 vs. 8.6, <italic toggle="yes">p</italic> = 0.071) showed no significant differences between the venlafaxine group and placebo group at 6 months. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A significant reduction in the HADS depression scores was observed between the two groups both at 3 months (6.41 vs. 8.81, <italic toggle="yes">p</italic> &lt; 0.001) and at 6 months</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 months</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kristensen et al. (2019) [<xref rid="B26-ijms-26-06514" ref-type="bibr">26</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antidepressants (SNRI, SSRI, TCA, Mirtazapine and others)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42,890 IBD patients were included (UC: 69.5%; CD: 30.5%).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Population-based cohort study Patients with CD or UC were recruited from the Danish National Patient Register (2000&#8211;2017). Information on antidepressant use and proxy measures of disease activity (healthcare and drug utilization) was extracted. Disease activity rates by antidepressant use adjusted for confounders were estimated with Poisson regression. The analyses were performed stratified by IBD subtype and type of antidepressants.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">As surrogate markers of disease relapse the primary outcomes were defined as either (1) hospitalization with IBD as the primary diagnosis; (2) surgery associated with IBD or (3) step-up medication in terms of a redeemed prescription of corticosteroids.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The antidepressant group had a significantly lower relapse rate (IRR, 0.85; 95% CI, 0.81&#8211;0.90) compared with the other patients. The association was more pronounced in patients with CD compared with UC patients. Patients with no prior use of antidepressants before IBD onset had a favorable influence on the disease course when exposed to antidepressants compared with nonusers.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 years (2000&#8211;2017)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chojnacki et al. (2011) [<xref rid="B33-ijms-26-06514" ref-type="bibr">33</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tianeptine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 UC patients in remission.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial:<break/>
Patients were divided in 2 groups of 30 subjects: the first (group 1) received aminosalicylates (2.0 g daily) and tianeptine (3 &#215; 12.5 mg) and the second (group 2) received placebo. Symptoms of anxiety, depression and IBD clinical activity were assessed and compared between the two groups every 3 months for 1 year.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCDAI, hemoglobin and CRP were evaluated to assess disease activity.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anxiety and depression were assessed, respectively, with Hamilton Anxiety Rating Scale-HARS and Back Depression Inventory-BDI.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">At 12 months, a significant decrease in disease activity index (respectively, 3.05 &#177; 1.36 and 4.65 &#177; 1.69), insignificantly lower level of CRP (7.00 5.65 and 9.41 &#177; 10.12) and higher level of hemoglobin (11.93 &#177; 0.83 and 11.0 &#177; 0.70) were observed in the tianeptine group compared with placebo group.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After 12 months, significant decreases in anxiety (from 20.35 &#177; 4.03 to 12.65 &#177; 3.78 points) and depression (from 19.95 &#177; 4.49 points to 9.60 &#177; 2.76 points) were observed in the tianeptine group compared with placebo group.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 months</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hall et al. (2018) [<xref rid="B25-ijms-26-06514" ref-type="bibr">25</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.3% SSRI<break/>
31.5% TCA<break/>
3.7% SNRI<break/>
3.7% both SNRI and TCA<break/>
1.9% trazodone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">331 patients with an established radiological, endoscopic or histological diagnosis of CD or UC.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal cohort study:<break/>
Cohort 1: 54 patients treated with antidepressant at baseline.<break/>
Cohort 2: 277 patients not treated with antidepressant<break/>
Participants were followed for a minimum period of 2 years to assess the occurrence of 4 clinical endpoints.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal disease activity was assessed with 4 outcomes:<break/>
<list list-type="simple"><list-item><label>-</label><p>disease flares or need for glucocorticoids;</p></list-item><list-item><label>-</label><p>escalation of medical therapy;</p></list-item><list-item><label>-</label><p>hospitalization;</p></list-item><list-item><label>-</label><p>intestinal resection</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anxiety and depression data were collected at baseline using the hospital anxiety and depression scale (HADS).<break/>
Somatization data were collected at baseline using the patient health questionnaire-15 (PHQ-15).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">During longitudinal follow-up, there was a trend towards lower rates of any of the four endpoints of IBD activity in patients with abnormal anxiety scores at baseline and who were receiving an antidepressant (42.3% versus 64.6%, <italic toggle="yes">p</italic> = 0.05). Based on univariate Cox regression analysis, there was a trend towards lower rates of escalation of medical therapy among patients receiving antidepressants at baseline (HR = 0.59; 95% CI 0.35&#8211;1.00, <italic toggle="yes">p</italic> = 0.05).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-year follow-up</td></tr></tbody></table><table-wrap-foot><fn><p>Crohn&#8217;s disease (CD); Ulcerative colitis (UC); Inflammatory bowel disease (IBD); Crohn&#8217;s Disease Activity Index (CDAI); Mayo Clinic Disease Activity Index (MCDAI); C-reactive protein (CRP); Erythrocyte Sedimentation Rate (ESR); albumin (ALB); white blood cells (WBC); selective serotonin reuptake inhibitors (SSRIs); serotonin noradrenergic reuptake inhibitors (SNRIs); Tricyclic Antidepressant (TCA); Inflammatory Bowel Disease Questionnaire (IBDQ); Hospital Anxiety and Depression Scale (HADS), World Health Organisation Quality of Life questionnaire (WHOQoL); Not Available (N/A); Quality of Life (QoL); Lichtiger Colitis Activity Index (LCAI); Short Form-36 (SF-36) and Arizona Sexual Experience Scale (ASEX); Hazard Ratio (HR).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-26-06514-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-26-06514-t002_Table 2</object-id><label>Table 2</label><caption><p>Included studies on antiepileptics for gastrointestinal outcomes in IBD patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Outcomes</th><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Results</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Author (Year), Ref.</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Population</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychiatric Condition</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychiatric Condition</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Follow-Up</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crockett et al. (2014), [<xref rid="B38-ijms-26-06514" ref-type="bibr">38</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topiramate</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1733 IBD subjects <break/>
CD = 955<break/>
UC = 755<break/>
IBD-U = 23</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective cohort study <break/>
Study group (n = 775) treated with Topiramate (&#8804;50 mg/day and &#8805;100 mg/day dose) Control group (n = 958) treated with comparator drugs (other anticonvulsant and anti-migraine medications)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: new prescription for an oral steroid (&#8805;14 days). Secondary: initiation of biologic agents, abdominal surgery, and hospitalization</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topiramate use was not associated with the primary outcome of steroid prescriptions (HR 1.14, 95% CI 0.74, 1.73). Results did not differ significantly by IBD subtype. There is no difference between the cohorts respect to post-exposure initiation of biologic agents (HR 0.93, 95% CI 0.35, 2.52), abdominal surgery (HR 1.22, 95% CI 0.70, 2.12), or hospitalization (HR 0.78, 95% CI 0.49, 1.26).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median follow-up of 2.8 months</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D&#8217;Onofrio et al. (2024) [<xref rid="B39-ijms-26-06514" ref-type="bibr">39</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pregbalin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 CD patient</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case Report</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assessment of HBI, SES-CD and CRP after therapy with pregabalin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After 2 months of treatment:<break/>
HBI dropped from 9 to 4 and CRP normalized.<break/>
After 6 months of treatment SES-CD dropped from 17 to 6.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 months</td></tr></tbody></table><table-wrap-foot><fn><p>Crohn&#8217;s disease (CD); Ulcerative colitis (UC); IBD-unclassified (IBD-U); Inflammatory bowel disease (IBD); Harvey Bradshaw index (HBI); Simple Endoscopic Score for Crohn&#8217;s Disease (SES-CD); Not Available (N/A); C-reactive protein (CRP); Hazard Ratio (HR).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-26-06514-t003" orientation="portrait"><object-id pub-id-type="pii">ijms-26-06514-t003_Table 3</object-id><label>Table 3</label><caption><p>Included study on mood stabilizers for gastrointestinal outcomes in IBD patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Outcomes</th><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Results</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Author (Year), Ref.</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease Type</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Population</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychiatric Condition</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychiatric Condition</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Follow-Up</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zisook et al. (1972) [<xref rid="B42-ijms-26-06514" ref-type="bibr">42</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lithium carbonate</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report <break/>
67 years old man with cyclic manic-depressive psychosis and UC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of lithium carbonate in the manic phase of the patient with also frequent, bloody stools with recent endoscopic findings of &#8220;severe, active ulcerative colitis, already on salicosulfapiridine (azulfadine) therapy&#8221;.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After 5 days of therapy evidence of marked improvement in frequency of evacuations and bleeding.<break/>
After two months endoscopic evidence of revealed marked improvement with only a few small bleeding points.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No more overtly psychotic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 months</td></tr></tbody></table><table-wrap-foot><fn><p>Ulcerative colitis (UC); Not Available (N/A).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-26-06514-t004" orientation="portrait"><object-id pub-id-type="pii">ijms-26-06514-t004_Table 4</object-id><label>Table 4</label><caption><p>Included studies on other psychiatric medications for gastrointestinal outcomes in IBD patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Outcomes</th><th colspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Results</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Author (Year), Ref.</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Population</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychiatric Condition</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBD</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychiatric Condition</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Follow-Up</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Furlan et al. (2006) [<xref rid="B48-ijms-26-06514" ref-type="bibr">48</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clonidine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 UC patients <break/>
20 controls</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial <break/>
First part: UC patients were compared with 20 healthy controls regarding the neural autonomic profile.<break/>
Secondo part: a subgroup of 16 patients randomly assigned to 8-wk transdermal clonidine (15 mg/weeks, 9 subjects), or placebo (7 patients).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DAI and endoscopic pattern before and after clonidine/placebo.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Changes in the autonomic profile after clonidine were associated with a reduction in the DAI score. Normalization of the autonomic profile with clonidine was accompanied by an improvement of the disease and a general increase in sympathetic activity characterized active UC.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 weeks</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lechin et al. (1985) [<xref rid="B47-ijms-26-06514" ref-type="bibr">47</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clonidine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 UC patients with at least one year of disease duration and severe activity (10 or more bloody stools per day for 15 or more days, not treated with steroids or sulfasalazine in the previous three months)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Double-blind Clinical Trial Prednisone (n = 15) 20 mg tid. Sulfasalazine (n = 15) 1.5 mg tid. Clonidine (n = 15) 0.3 mg tid. Each group was treated for three six-week periods, separated by two six-week placebo periods.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assessment of rating scales for clinical, endoscopic, histologic, and radiologic changes. biochemical parameters. Distal colon motility changes.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clonidine and prednisone were effective in treating idiopathic UC. Both drugs were more effective than sulfasalazine. Furthermore, clonidine potentiated prednisone and sulfasalazine effects.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 weeks followed by an open<break/>
evaluation of at least one year</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lie et al. (2018) [<xref rid="B43-ijms-26-06514" ref-type="bibr">43</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naltrexone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47 IBD patients (CD = 28<break/>
UC = 19)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial:<break/>
participants were steroid dependent or steroid refractory with clinical active disease at initiation of LDN (4.5 mg Naltrexone once daily) therapy. 87.2% previously received at least one anti-TNF&#945; agent. 40.4% had been treated with two anti-TNF&#945; agent.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical response = self-assessed disease activity decreased within the first 4 weeks of therapy and lasted for at least 4 weeks. Endoscopic findings were scored from 0 to 3, (no inflammation to severe inflammation)<break/>
Consecutive endoscopies were performed at baseline and at 12 weeks or at time of relapse, whichever occurred earlier.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>35 (74.5%) achieved a clinical response.</p></list-item><list-item><label>-</label><p>No statistically significant difference between CD and UC</p></list-item><list-item><label>-</label><p>Clinical remission had a significantly greater improvement in endoscopic score compared to not clinical response (median change &#8722;1.5, range &#8722;2 to 0 versus 1.0, range 0&#8211;2, p = 0.005).</p></list-item><list-item><label>-</label><p>6 patients with response and 6 patients with remission had consecutive endoscopies evaluation and no significant difference was observed in baseline endoscopic score for response and remission.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 weeks</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paulides et al. (2022) [<xref rid="B49-ijms-26-06514" ref-type="bibr">49</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naltrexone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">122 patients with mild to moderately active CD, defined by endoscopy SES-CD of 3&#8211;15.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized, double-blinded, placebo-controlled multicenter clinical trial: <break/>
<list list-type="simple"><list-item><label>-</label><p>61 patients = LDN 4.5 mg once daily</p></list-item><list-item><label>-</label><p>61 patients = placebo, for 12 weeks.</p></list-item><list-item><label>-</label><p>After 12 weeks patients are invited to an open label exploration extension study until week 52.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary objective defined as SES-CD &#8804;2 and an ulcerated surface subscore &#8804;1 in all five segments at week 12.<break/>
Secondary:<break/>
<list list-type="simple"><list-item><label>-</label><p>Steroid free clinical remission (HBI score of &#8804;4 complete tapering of systemic corticosteroids)</p></list-item><list-item><label>-</label><p>Clinical Response (decrease in HBI of &#8805;3 points compared with baseline)</p></list-item><list-item><label>-</label><p>Endoscopic response (reduction in SES-CD score by &#8805;50% vs. baseline at week 12).</p></list-item><list-item><label>-</label><p>Changes in laboratory inflammation (CRP and FC) at week 12, 24 and 52.</p></list-item><list-item><label>-</label><p>Steroid free clinical remission at week 52.</p></list-item><list-item><label>-</label><p>Endoscopic remission and response at week 52.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Quality of life, via the SIBDQ and EQ5D.</p></list-item><list-item><label>-</label><p>Fatigue, ia the FACIT-F and MFI.</p></list-item><list-item><label>-</label><p>Anxiety, depression and sleep disturbance, via the PROMIS NIH.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ongoing study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ongoing study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52 weeks</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smith et al. (2011) [<xref rid="B44-ijms-26-06514" ref-type="bibr">44</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naltrexone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 CD patients with moderate to severe activity (CDAI of &#8805;220)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized double-blind placebo-controlled study. <break/>
<list list-type="simple"><list-item><label>-</label><p>18 patients = naltrexone 4.5 mg</p></list-item><list-item><label>-</label><p>16 patients = placebo</p></list-item><list-item><label>-</label><p>32 patients = naltrexone 4.5 mg the open-labeled extend study (additional 12 weeks)</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary outcome: clinical response (70-point decline in CDAI scores from baseline values at 12 weeks). <break/>
Secondary outcome: <break/>
<list list-type="simple"><list-item><label>-</label><p>endoscopic healing with colonoscopy and biopsies.</p></list-item><list-item><label>-</label><p>endoscopic response (5-point decline in CDEIS)</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="simple"><list-item><label>-</label><p>88% of active arms had at least a 70-point decline in CDAI scores compared to 40% of placebo (<italic toggle="yes">p</italic> = 0.009).</p></list-item><list-item><label>-</label><p>78% of active arm exhibited an endoscopic response compared to 28% response in placebo-treated controls (<italic toggle="yes">p</italic> = 0.008),</p></list-item><list-item><label>-</label><p>33% of active arm achieved remission with a CDEIS compared to 8% of placebo.</p></list-item></list>
Open labeled: <break/>
<list list-type="simple"><list-item><label>-</label><p>patients who continued naltrexone therapy had a further 75- point decline in CDAI scores (<italic toggle="yes">p</italic> &lt; 0.01) -24-week score was also significant compared to baseline (<italic toggle="yes">p</italic> &lt; 0.0001).</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 weeks (+additional 12 weeks)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smith et al. (2007) [<xref rid="B45-ijms-26-06514" ref-type="bibr">45</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naltrexone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 = CD treated with 4.5 mg naltrexone/day. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Open-labeled pilot prospective trial including CD patients with activity index (CDAI) score of 220&#8211;450, with no active biological therapy treated with naltrexone.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDAI scores were assessed pretreatment, every 4 weeks on therapy and 4 weeks after completion of the study drug. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IBDQ and the short-form (SF-36) quality of life surveys</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDAI scores decreased significantly (<italic toggle="yes">p</italic> = 0.01) with LDN, from baseline to 4 weeks after completing therapy. <break/>
89% of response (<italic toggle="yes">p</italic> &lt; 0.001)<break/>
67% of remission. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improvement in both quality-of-life surveys with LDN compared with baseline</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 weeks</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smith et al. (2013) [<xref rid="B46-ijms-26-06514" ref-type="bibr">46</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naltrexone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD = 12 (pediatric patients mean age of 12.3 years) moderate to severe Crohn&#8217;s disease (PCDAI of &gt;30), not in therapy with steroids greater than 10 mg daily, anti-TNF&#945; agents</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pilot clinical trial <break/>
Study group: 6 CD treated with naltrexone (0.1 mg/kg)<break/>
Placebo: 6 CD<break/>
11 CD = open-labeled treatment with 8 additional weeks of naltrexone. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary outcome: safety and tolerability compared to placebo. <break/>
secondary outcome: clinical response with 10-point decline in PCDAI scores compared to baseline/pretreatment values.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quality of life was monitored by the Impact III survey.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>naltrexone was well tolerated without any serious adverse events -PCDAI scores significantly decreased from pretreatment values (34.2 &#177; 3.3) with an 8-week course of naltrexone therapy (<italic toggle="yes">p</italic> = 0.005).</p></list-item><list-item><label>-</label><p>25% of those treated with naltrexone were considered in remission (score &#8804;10) and 67% had improved with mild disease activity (decrease in PCDAI score by at least 10 points) at the end of the study.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic and social quality of life improved with naltrexone treatment (<italic toggle="yes">p</italic> = 0.035).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 weeks</td></tr></tbody></table><table-wrap-foot><fn><p>Crohn&#8217;s disease (CD); Ulcerative colitis (UC); Crohn&#8217;s Disease Activity Index (CDAI); Disease Activity Index (DAI); Harvey Bradshaw index (HBI); Simple Endoscopic Score for Crohn&#8217;s Disease (SES-CD); Not Available (N/A); C- reactive protein (CRP); Fecal calprotectin (FC); Inflammatory Bowel Disease Questionnaire (IBDQ); Hospital Anxiety and Depression Scale (HADS), World Health Organization Quality of Life questionnaire (WHOQoL); Not Available (N/A); Quality of Life (QoL); Short Inflammatory Bowel Disease Questionnaire (SIBDQ); Ter in die (tid); CDEIS (Crohn&#8217;s Disease Endoscopic Index of Severity); Pediatric Crohn&#8217;s Disease Activity Index (PCDAI); 5-level EQ-5D version (EQ-5D-5L); Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F); Multi-Dimensional Fatigue Inventory (MFI); Patient-Reported Outcomes Measurement Information System (PROMIS); Low dose Naltrexone (LDN); Tumor Necrosis Factor (TNF).</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>